



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 7/06, 14/655, A61K 38/02, 38/08, 38/10, 38/16, 38/31, 35/60, 39/00		A1	(11) International Publication Number: WO 97/44352 (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: PCT/AU97/00312 (22) International Filing Date: 22 May 1997 (22.05.97) (30) Priority Data: PN 9990 22 May 1996 (22.05.96) AU		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): NORTHSTAR BIOLOGICALS PTY. LTD. [AU/AU]; 8 Woods Street, Balwyn, VIC 3103 (AU).		Published <i>With international search report.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): GERRATY, Norman, L. [AU/AU]; 9 Harleston Drive, Mount Eliza, VIC 3930 (AU). WESTBROOK, Simon, L. [AU/GB]; Northstar Biologicals Pty. Ltd., 8 Woods Street, Balwyn, VIC 3103 (AU). KINGSTON, David, J. [AU/AU]; 5 Shallot Close, Glen Waverley, VIC 3150 (AU).			
(74) Agent: SANTER, Vivien; Griffith Hack, 509 St. Kilda Road, Melbourne, VIC 3004 (AU).			
(54) Title: MODULATING THE ACTIVITY OF HORMONES OR THEIR RECEPTORS - PEPTIDES, ANTIBODIES, VACCINES AND USES THEREOF			
(57) Abstract <p>This invention relates to immunogenic, non-naturally occurring peptides and immunologically reactive molecules thereto which modulate the activity of hormones or the receptors therefor. These peptides are based on portions of somatostatin, somatostatin receptors and insulin-like growth factor binding protein. Methods of modulating hormonal activity in an animal and compositions therefor are also contemplated.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

- 1 -

MODULATING THE ACTIVITY OF HORMONES OR THEIR RECEPTORS - PEPTIDES, ANTIBODIES, VACCINES AND USES THEREOF

FIELD OF THE INVENTION

The present invention relates to peptides, 5 immunologically reactive molecules (IRM) specific for the peptides, pharmaceutical compositions including vaccines incorporating the peptides or IRM and to uses of these in animals.

10 BACKGROUND

Over the past three decades alternative methods, other than genetic selection and dietary manipulation, have been sought to improve/modulate the efficiency of animal production; for example liveweight gain, improved 15 efficiency of utilisation of feed, milk yield, wool production, survival rate and body composition. The techniques implemented to achieve such outcomes have been based upon the administration of exogenous hormones and/or the production of transgenic animals.

20 Animal welfare issues and increasing consumer and government antipathy towards the use of exogenous hormone treatments and transgenic technology have led researchers to explore alternative "drug free" methods of improving the efficiency of animal production. Over 25 the past decade attention has been focused on the possibility of utilising the immune response to manipulate the endocrine system.

There are examples reported in the scientific literature of antibody-mediated enhancement or 30 suppression of growth, body composition, appetite, and reproductive physiology. These include luteinizing hormone (LH), thyroid-stimulating hormone (TSH; Melmed et al., 1980), inhibin (Scanlon et al., 1993), growth hormone (Pell and James, 1995), insulin like growth 35 factor (Pell and Aston, 1995), prolactin (Lindstedt,

- 2 -

1994), growth hormone releasing factor (Moore *et al.*, 1992), vasopressin (Kamoi *et al.*, 1977), somatostatin (Westbrook *et al.*, 1993), gastrin (Dockray and Taylor, 1976), cholecystokinin (CCK; Pekas and Trout, 1993), 5 testosterone (Thomson *et al.*, 1985), progesterone (Kaushansky *et al.*, 1977), prostaglandin F_{2α} (PGF_{2α}; Crowe *et al.*, 1995), and adrenocorticotropin (ACTH; Wynn *et al.*, 1995).

The reasons for attempting to elicit immune 10 responses to "self" hormones are varied. These include efforts to improve the production of farm animals; by increasing meat quality, reducing back-fat, promoting appetite, enhancing liveweight gain, improving milk production, altering the constituents of milk, and 15 manipulating fertility. In addition there has been interest in easing labour requirements associated with farm management, overcoming disease and gaining a greater understanding of endocrine and autocrine interactions.

20 Of all the peptide, protein and steroid antigens listed above, only two commercial preparations based on immunological manipulation of endogenous hormones appear to be available. These are Fecundin®, an androstenedione antigen, which results in an improved 25 fecundity (Scaramuzzi *et al.*, 1977), and Vaxtrate®, a LHRH antigen, which induces immuno-neutralisation of LHRH with resulting inhibition of steroidogenesis in the ovaries and testes of cattle (Hoskinson *et al.*, 1990).

30 SUMMARY OF THE INVENTION

In work leading up to the invention the inventors produced a number of peptides based on native hormones, or receptors of native hormones and administered these to animals. Administration of the

- 3 -

peptides together with an adjuvant resulted in a number of economically significant effects in the animals such as improved live weight gain, improved milk production, improved wool production, meat quality, efficiency of 5 food utilisation and the like.

Thus the invention provides a series of peptides, of various amino acid sequences which are capable of eliciting specific antibodies that alter an array of physiological functions in animals. These 10 physiological functions include digestion, nutrient uptake and metabolism of absorbed substrates, which result in improved productive capacities of immunised animals. Particularly notable are the modifications of the gastrointestinal tract resulting in improved 15 digestion and associated benefits.

In a first aspect the present invention provides a non-naturally occurring peptide with an amino acid sequence which is derived from, or is similar to a native animal hormone, carrier protein, binding protein 20 or receptor for said hormone, wherein said peptide is capable of eliciting one or more antibodies which are able to modulate the activity of said hormone or receptor *in vivo*.

The term "non-naturally occurring" means that 25 the peptide is not the same as that produced by protein synthesis in nature but is produced by the human hand. Peptides may be produced by standard peptide synthesis techniques, or by recombinant DNA techniques or the like.

30 The term "peptide" refers to any molecule formed at least partly of amino acids wherein the amino acids are joined by peptide bonds. The peptides may be made up of only a few amino acids or may be polypeptides. Therefore, proteins and microproteins are also 35 encompassed by this term. The amino acids comprising

the peptides may be naturally occurring or synthetic amino acids. The peptides may be essentially amino acid sequences, and may also comprise non-amino acid components such as carbohydrates or fatty acids, or 5 comprise non-natural amino acid-like structures.

The term "amino acid sequence derived from, or is similar to" used above refers to the fact that the amino acid sequence may be based on a native sequence or be similar to a native sequence. The term "derived 10 from" does not indicate the actual origin of the peptide (as it may be synthetic or recombinant in origin) but indicates a peptide at least partly homologous to the native hormone or receptor. The peptide is of course different to the native hormone or receptor in that it 15 may comprise a fragment thereof or two or more non-contiguous fragments thereof. It may also comprise other amino acids not present in the native hormone or receptor.

The term "native animal hormone, carrier 20 protein, binding protein or receptor of the hormone" refers to hormones, carrier proteins, binding proteins or receptors which occur in animals. This may be any type of animal but is preferably a vertebrate, more preferably a mammal.

25 The term "capable of eliciting one or more antibodies" refers to the ability of the peptide to elicit or stimulate what appears to be primarily an antibody mediated immune response. There may be some cell mediated immunity involved also. The peptide may 30 not be able to stimulate an immune response by itself especially in the case of small peptides which may need to be present on a carrier molecule. Nonetheless such a peptide still falls within the definition of "capable of eliciting one or more antibodies".

- 5 -

The term "able to modulate the activity of said hormone or receptor *in vivo*" refers to the ability of the antibody to alter, adjust or vary the activity of the hormone or its receptor in a live animal. The 5 alteration, adjustment or variation will generally be in the form of a down regulation or inhibition of the hormone or receptor although other effects such as an increase in hormone or receptor activity are also contemplated.

10 Preferably the peptide is not biologically active. Although it is based on a native hormone or receptor, preferably the peptide does not have the biological activity of that hormone or receptor.

15 The peptide may be based on any hormone or receptor involved in regulating physiological functions.

20 Preferably the peptides are able to elicit antibodies to the following hormones or hormone receptors: somatostatin, glucagon, gastrin, cholecystokinin, somatostatin receptors, insulin-like growth factor binding proteins (IGFBP). In one embodiment, the peptides elicit antibodies to hormones of the reproductive tract, in particular luteinising hormone releasing hormone (LHRH), hormones of the adrenal gland, such as adrenal corticotropic hormone 25 (ACTH), or of the stomach such as gastrin and cholecystokinin.

30 The inventors have produced a number of peptides based on portions of somatostatin (Patel 1992), somatostatin receptors (SSTR) (Resine & Bell, 1995) and insulin-like growth factor binding protein 1 to 4 (IGFBP) (Cohick & Clemmons, 1993).

35 In a particularly preferred aspect the invention provides a non-naturally occurring peptide with an amino acid sequence based on that of somatostatin (SRIF). The preferred sequence produces antibodies which

- 6 -

preferentially target SSTR2, SSTR3 and SSTR5, in contrast to somatostatin which produces antibodies that bind to the receptor comprising SSTR1 to 6.

5 The peptide of the invention is able to increase levels of circulating insulin, IGF-I and IGF-II and, increase levels of anabolism, decrease gastric activity and/or improve digestion in an animal.

10 More particularly the invention provides a peptide having the following sequence as represented by the single letter amino acid code:

LCFWWKTC (SEQ ID NO: 1)

15 This peptide binds to and produces antibodies which exhibit an affinity for SSTR2, SSTR3 and SSTR5 of the somatostatin receptor. Without wishing to be bound by any proposed mechanism for the observed advantages, it appears that the sequence
F-W-K-T is the key to blocking of SSTR2, SSTR3 and SSTR5.

20 The invention also relates to a derivative or variant of SEQ ID NO:1 in which the size and the shape of the exposed rings of the antigen are the smallest diameter possible.

25 SEQ ID NO:1 is a relatively soluble peptide in sterile physiological saline.

30 Preferably, the peptide is presented as a cyclised sequence, e.g.:

F-C-F-W-K-T-C-F-C (SEQ ID NO:2) or

35 C-F-W-K-T-C-S-G (SEQ ID NO:3)

30

The peptide comprising the core sequence FWKT may also be cyclised by means other than inclusion of cysteine residues which form disulphide bonds. A particularly preferred form of the cyclic peptide of the invention is one wherein the linking group or sequence

- 7 -

is as short as possible, and the structural configuration is one which allows the portion of the molecule comprising FWKT to bind to the somatostatin receptor. In a more particularly preferred embodiment, 5 the spatial configuration corresponding to the sequence FWKT in the cyclic peptide is that it occupies minimal space. Ideally, the arc in the cyclic peptide that is formed by the sequence FWKT is as small as possible and complements its target receptor.

10 A cyclic peptide which stimulates production of antibodies with an affinity for SSTR2, 3 and 5 is particularly preferred.

The peptide may also be presented as a linear peptide singly, e.g:
15 F-W-K-T-S-G-G (SEQ ID NO:4)
or as a dimer, e.g:
F-W-K-T-S-T-K-T-S-T-K-W-F (SEQ ID NO:5)

20 In yet another embodiment, the invention provides an immunogenic protein or molecule which comprises a sequence which produces antibodies which have a particular affinity for SSTR2, 3 and 5. The protein or molecule may be of any type as long as the binding of antibodies to the receptors is stimulated.

25 In another preferred aspect the invention provides a non-naturally occurring peptide with an amino acid sequence which is at least partly homologous to a native animal hormone receptor, wherein said peptide is capable of eliciting one or more antibodies which are 30 able to modulate the activity of said receptor *in vivo*

In a particularly preferred aspect the invention provides a non-naturally occurring peptide with an amino acid sequence at least partly homologous to that of a somatostatin receptor (SSTR). Such peptides have the

5 ability to increase at least one biological activity selected from the group consisting of weight gain, birth weight, growth rates, milk production, levels of circulating insulin, IGF-I and IGF-II, fibre production, milk production, and muscle weight.

10 More particularly preferred is a peptide having an amino acid sequence homologous to amino acid residues 1 to 11, 30-57 and/or between the sixth and seventh transmembrane domain of SSTR. The transmembrane domain in question has been reported to occur at residues 274 to 305. The amino acid positions for SSTR are relative to the NH₃⁺ terminal of the SSTR for all vertebrate species. Preferably the peptide is based on SSTR from humans, pigs, cattle, mice or rats. The peptides may be based on SSTRs from other species such as sheep, goats, 15 camels, llamas, alpacas, chickens, ducks, turkeys, ostriches, emus and fish.

20

25

Still more particularly the invention provides a peptide having the following sequence as represented by the single letter amino acid code, and derivatives and variants thereof:

SEQ ID NO	Peptide	Based on	Residue No.
6	MFPNGTASSPS	Human SSTR 1	1-11
7	QNGTLSEGQGS	Human SSTR 1	47-57
8	AEQDDATV	Human SSTR 1	297-305
9	MFPNGTASSPS	Mouse SSTR 1	1-11
10	QNGTLSEGQGS	Mouse SSTR 1	47-57
11	AEQDDATV	Mouse SSTR 1	297-305

- 9 -

12	MFPNGTAPSPT	Rat SSTR 1	1-11
13	QNGLTLSEGQGS	Rat SSTR 1	47-57
14	AEQDDATV	Rat SSTR 1	297-305
15	MDMADEPL	Human SSTR 2	1-8
16	QTEPYYDLTSN	Human SSTR 2	32-42
17	AISPTPALL	Human SSTR 2	282-290
18	MDLVSEL	Bovine SSTR 2	1-7
19	QTEPYYDLASN	Bovine SSTR 2	31-41
20	AISPTPALL	Bovine SSTR 2	281-289
21	MDMAYELL	Porcine SSTR 2	1-8
22	QTEPYYDLTSN	Porcine SSTR 2	32-42
23	AISPTPALL	Porcine SSTR 2	282-290
24	MEMSSEQL	Mouse SSTR 2	1-8
25	QTEPYYDMTSN	Mouse SSTR 2	31-41
26	AISPTPALL	Mouse SSTR 2	282-290
27	MELTSEQF	Rat SSTR 2	1-8
28	QTEPYYDMTSN	Rat SSTR 2	30-40
29	AISPTPALL	Rat SSTR 2	283-291
30	MDMLHPS	Human SSTR 31-7	1-7
31	AGPSPAGLAVS	Human SSTR 3	31-41
32	PLPEEPAF	Human SSTR 3	283-291
33	MATVTYPS	Mouse SSTR 3	1-8
34	AGTSLAGLAVS	Mouse SSTR 3	32-42
35	PLPEEPAF	Mouse SSTR 3	284-292
36	MAAVTYPS	Rat SSTR 3	1-8
37	AGTSLAGLAVS	Rat SSTR 3	32-42
38	PLPEEPAF	Rat SSTR 3	284-292
39	MSAPSTLPP	Human SSTR 4	1-9
40	GPGDARAAGMV	Human SSTR 4	31-41
41	TSLDATV	Human SSTR 4	282-290
42	MNTPATLPL	Rat SSTR 4	1-9
43	SDGTGTAGMV	Rat SSTR 4	31-41
44	TSLDATV	Rat SSTR 4	282-290
45	MEPLFPA	Human SSTR 5	1-7

- 10 -

46	VGPAPSAGAR	Human SSTR 5	30-40
47	ALPQEPAS	Human SSTR 5	282-290
48	MEPLSLA	Rat SSTR 5	1-7
49	VGSASPMGAR	Rat SSTR 5	33-43
50	TLPEEPTS	Rat SSTR 5	283-291

The term "derivatives and variants" thereof refers to peptides with different amino acid sequences having substantially the same or similar antigenic 5 activity. Such derivatives or variants may have amino acid substitutions, insertions or deletions compared to the preferred sequences listed above. Typical substitutions are those made in accordance with Table 1 below.

- 11 -

Table 1
Suitable residues for amino acid substitutions

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>
5	Ala	Ser
	Arg	Lys
	Asn	Gln; His
	Asp	Glu
	Cys	Ser
	Gln	Asn
10	Glu	Ala
	Gly	Pro
	His	Asn; Gln
	Ile	Leu; Val
	Leu	Ile; Val
15	Lys	Arg; Gln; Glu
	Met	Leu; Ile
	Phe	Met; Leu; Tyr
	Ser	Thr
	Thr	Ser
20	Trp	Tyr
	Tyr	Trp; Phe
	Val	Ile; Leu

25 Where the peptide is derivatised by amino acid substitution, the amino acids are generally replaced by other amino acids having like properties such as hydrophobicity, hydrophilicity, electronegativity, bulky side chains and the like. Amino acid substitutions are 30 typically of single residues. Amino acid insertions will usually be in the order of about 1-10 amino acid residues and deletions will range from about 1-20 residues. Preferably, deletions or insertions are made in adjacent pairs, i.e. a deletion of two residues or 35 insertion of two residues.

- 12 -

For example, the peptide of the invention in the cyclised or cyclic form may be varied by substitution of some of the key amino acids with similar amino acids, or amino acid-like structures. A particularly preferred 5 sequence is:

NMe-Y-D-T-K-V-F-C-S (SEQ ID NO:51)

although this sequence is very poorly soluble in sterile 10 saline solutions.

Piglets suckling dams which had been vaccinated with this molecule in the last trimester of pregnancy grew an average of 40% faster from birth to weaning than did corresponding piglets which were suckling non- 15 immunised dams.

The peptides and immunologically active molecules of the invention may be administered as the sole active agent, or be co-administered with one or more other agents. For example, SEQ ID NO:1 can be co- 20 administered with gastrin and/or cholecystokinin, together with a suitable carrier.

In one embodiment, sequences such as SEQ ID NO:2 to 5 may be co-presented as separate peptides or as one peptide molecule comprising sequences specifically 25 targeting other hormones such as gastric hormones. An example of such a sequence is:

A-Y-M-G-W-S-C-T-K-W-F (SEQ ID NO:52)

When this antigen was injected three times into 30 growing lambs with the preferred delivery vehicle (oil), anti-SRIF and anti-cholecystokinin antibodies were detectable at 84 days of age. By this time, the immunised lambs had grown an average of 20% more than 35 non-immunised lambs.

Reproductive hormones may also be targetted and an example of a sequence for co-administration with the peptide preferred for this invention is:

5 F-W-K-T-S-K-H-W-S-Y-G-L-R-D-G-C (SEQ ID NO:53)

Male pigs immunised with this peptide three times from 12 weeks of age grew an average of 12 weeks faster than non-immunised pigs to 24 weeks of age, and
10 the testicle size of the immunised pigs was approximately 50% the size of those of the non-immunised animals.

In a particularly preferred aspect the invention provides a non-naturally occurring peptide with an amino acid sequence at least partly homologous to insulin-like growth factor binding protein (IGFBP). Such peptides are able to modulate carbohydrate metabolism and thereby improve growth of animals. The peptides may also be useful in the prevention or treatment of diabetes.

20 More particularly preferred is a peptide which includes in its sequence a portion of a native IGFBP which binds insulin-like growth factor, preferably at least some of the region of residues 1 to 10 or 1 to 13 of a native IGFBP. The amino acid residues are relative
25 to the NH₃⁺ terminal of IGFBP. Preferably the peptide is based on IGFBP from humans, pigs, cattle, mice or rats. The peptide may also be based on IGFBPs from other species such as sheep, goats, camels, llamas, alpacas, chickens, ducks, geese, turkeys, ostriches,
30 emus and fish.

Still more particularly the invention provides a peptide having one of the following sequences as represented by the single letter amino acid code, or a derivative or variant thereof.

SEQ NO.	ID	Peptide	Based on	Residue No.
54		FRCPPCTERLAA	Rat IGFBP	11-12
55		EVLFRCPPCTPE	Rat IGFBP 2	1-12
56		GAGAVGAPVV	Rat IGFBP 3	1-12
57		DEAIHCPPCSEE	Rat IGFBP 4	1-12

The peptides of the invention may be referred to herein as "peptides based on SSTR or peptides based on 5 IGFBP", for example. Peptides may be based on one or more hormones, carrier proteins or hormone receptors.

The peptides contemplated herein may be chemically synthesised, for example by solid phase peptide synthesis or may be prepared by subjecting the 10 native peptides to hydrolysis or other chemically disruptive processes to produce fragments of the molecule. Alternatively, the peptides may be made by *in vitro* or *in vivo* recombinant DNA synthesis. In this case, the peptides may need to be synthesised in 15 combination with other proteins and then subsequently isolated by chemical or enzymic cleavage, or the peptides or polyvalent peptides may be synthesised in multiple repeat units. The selection of a particular method of producing the subject peptides will depend on 20 factors such as the required type, quantity and purity of the peptides as well as ease of production and convenience.

Preferably the peptides of the invention are at least partially purified. More preferably the peptides 25 are in a substantially purified form.

In a second aspect the invention provides an immunologically reactive molecule (IRM) which is specific for the peptide of the first aspect of the invention.

The term "immunologically reactive molecule" refers to a molecule which is able to bind to another molecule, such as an antigen or a peptide capable of functioning as an antigen when present on a carrier.

5 Immunologically reactive molecules are typically antibodies including naturally occurring antibodies, recombinant antibodies, scantibodies, synthetic antibodies including fusions or chimeras of antibodies, and functional fragments of any of the foregoing, such

10 as Fab and $F(ab')_2$. Where the antibody IRM is a recombinant form, the molecule may be encoded by a naturally occurring or synthetic nucleotide sequence and expressed in any convenient expression system. Where the molecule is synthetic, it is conveniently prepared by

15 the step-wise addition of single amino acid groups or amino acid fragments of antibodies. With regard to the latter, the synthetic antibody may be a fusion or chimeric antibody comprising light or heavy chains derived from other antibodies.

20 Antibodies and other IRMs of the present invention may be of any animal origin, including from mammals such as humans, livestock animals, companion animals, wild animals and laboratory test animals (eg. mice, rats, rabbits and guinea pigs). An "animal" antibody also extends to an antibody from non-mammalian species such as birds, eg. chickens and other poultry, emus and ostriches.

25 Binding of the peptide or IRM may occur in the target hormone receptor site (usually by the use of biologically active antigenic sequences), or to areas of the cell membrane adjacent to the targeted receptor site, in which case the antigenic fragment has no biological activity.

30 In a third aspect the present invention provides a peptide of the first aspect of the invention coupled

- 16 -

to a suitable carrier such that a peptide/carrier complex is formed.

The peptide/carrier complex is particularly advantageous where the peptide is relatively small (MW 5 less than 10,000) and not particularly immunogenic when administered alone.

Suitable carriers are generally large molecules which are capable of coupling with the peptide. In order to elicit an immune response, the peptides generally 10 need to be coupled to carrier proteins, to make the antigen significantly "foreign" and to increase the molecular weight of the antigen. In general, it appears that the more foreign or the more immunogenic a carrier protein is to the vaccine recipient the greater the 15 antibody response is likely to be (Meloen, 1995). Large protein molecules, notably keyhole limpet haemocyanin, bovine serum albumin, bacterial toxins, ovalbumin and thyroglobulin (see Meloen, 1995), are used generally for conjugation to small molecular weight antigens; however 20 a multiple antigen presentation (MAP) system, for example poly-L-lysine, is preferred.

In a fourth aspect the present invention provides a pharmaceutical composition comprising an immunogenically effective amount of the peptide of the 25 first aspect of the invention, or an amount of the IRM of the second aspect of the invention sufficient to confer passive immunity, together with a pharmaceutically or veterinarianily acceptable carrier or excipient, and optionally comprising an adjuvant.

30 In the following description, the peptide of the present invention is referred to as the "active ingredient".

The active ingredient of the pharmaceutical composition is contemplated to exhibit excellent 35 activity in stimulating, enhancing or otherwise

facilitating a humoral immune response in animals when administered in an amount which depends on the particular case. For example, for about 0.5 µg to about 20 mg of protein which may be considered per kilogram of 5 body weight per day may be administered in one or more of daily, weekly or monthly or in other suitable time intervals or the dose may be proportionally reduced as indicated by the exigencies of the situation. The active compound may be administered by injection in a 10 convenient manner or via a genetic sequence in a viral or bacterial vector.

The active ingredient may also be administered in dispersions prepared in sterile physiological saline, glycerol, liquid polyethylene glycols, and/or mixtures 15 thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for *in vivo* administration include sterile aqueous solutions (where 20 water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. In all cases the form must be sterile and must be fluid to the extent that easy syringeability exists. It must be stable under the 25 conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, 30 propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the

case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, 5 sorbic acid, thormerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride, or gelling agents such as cyclodextrins, gelatin, alginate, and the like. Prolonged absorption of the injectable compositions can 10 be brought about by the use in the compositions of agents delaying absorption, for example.

Sterile injectable solutions are prepared by incorporating the active ingredient in the required amount in the appropriate solvent with various of the 15 other ingredients enumerated above, as required, followed by filtered sterilisation. Generally, dispersions are prepared by incorporating the various sterilised active ingredient(s) into a sterile vehicle which contains the basic dispersion medium and the 20 required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient 25 plus any additional desired ingredient from previously sterile-filtered solution thereof.

As used herein "pharmaceutically or veterinarily acceptable carriers and/or diluents" include any and all solvents, dispersion media, aqueous solutions, coatings, 30 antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically or veterinarily active substances is well known in the art. Except insofar as any conventional media or agent is 35 incompatible with the active ingredient, use thereof in

- 19 -

the composition is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

Preferably the pharmaceutical composition 5 comprises the protein coupled to a carrier. More preferably the pharmaceutical composition is in the form of a vaccine preparation.

Many substances may be used to deliver the peptide or molecules of the invention. High levels of 10 circulatory humoral antibodies to SRIF have been generated following immunisation with SRIF antigens in physiological saline, Freunds complete adjuvant (FCA), muramyl dipeptide (MDP), Freunds incomplete adjuvant (FIA & MDP), DEAE-dextran, and Quill A.

15 The invention also provides a novel delivery vehicle for the peptide of the invention, comprising an oil derived from a deep sea shark. Thus, in a fifth aspect, the invention provides a veterinarily or pharmaceutically acceptable carrier, comprising shark 20 oil which has immune adjuvant activity.

The oil is desirably of a type which stimulates antibody production in epithelial surfaces of the lung, the respiratory, gastrointestinal or urogenital tract, or the like. In a particularly preferred embodiment, 25 the oil enhances antibody secretion in the mucosa of the mammary gland, thereby producing immuno-active colostrum or milk.

The oil typically comprises the following components:

- 20 -

Hydrocarbons	nil - 2%
Wax esters	nil - 2%
Free fatty acids	less than 2%
Polar lipids	10-15%
5 Diacylglycerol ethers	30-50%
Triacyglycerols	40-70%

Approximately 80% of the fatty acids present are in the monounsaturated form.

10 The carbon chain length and proportion of the fatty acids of the typical oil are as follows:

Typical analysis

15	C14	1%-2%
	C15	>1%
	C16	18%-20%
	C17	1%-4%
	C18	42%-65%
20	C19	0.1%-2%
	C20	5%-15%
	C21	>1%
	C22	0.1%-18%
	C23	nil
25	C24	0%-5%

The oil is preferably alkoxyglycerol-rich in that it comprises a triacylglycerol with the general formula $\text{CH}_2\text{OH}.\text{CHOH}.\text{CH}_2\text{OR}$, where R is a long chain radical, primarily and preferably C_{16} and C_{18} .

Within this general structure, the following glycerol ethers are especially preferred:-

- 21 -

20-70% octadec - 9 - enylglyceryl ether
3-25% 1 hexadecylglyceryl ether
1- 15% hexadec - 7 - enylglyceryl ether
1.5-20% octadecyl glyceryl ether
5 1-15% eicosa - 9 - enylglyceryl ether

The following are preferably added to this oil:

1-25% lecithin
10 1-25% DL alpha tocopherol acetate
0-3% 1, 2, 5 - dihydroxycholecalciferol
0-5% vitamin A
0-40% non-mineral oil (typically having a
triacylglycerol structure)

15

In a sixth aspect the invention provides a method of producing an immunogenic composition, comprising the steps of contacting a peptide capable of eliciting an immune response with an oil and bringing 20 said peptide and oil into a form suitable for administration, wherein said oil comprises 30-50% diacylglycerol-ethers. Preferably, the ethers comprise:

20-70% octadec - 9 - enylglyceryl ether
25 3-25% 1 - hexadecylglyceryl ether
1-15% hexadec - 7 - enylglyceryl ether
1.5-20% octadecyl glyceryl ether
1-15% eicosa - 9 - enylglyceryl ether

30 1-25% lecithin as the emulsifying agent
1-25% DL alpha tocopherol acetate
0-3% 1,2,5-dihydroxycholecalciferol
0-5% vitamin A
0-40% non-mineral oil

In a particularly preferred embodiment, the immunogenic composition comprises peptide No. 1 emulsified with the oil ("FEEDMIZA").

5 The term "immunogenic composition" refers to a pharmaceutical or veterinary composition which is able to elicit an immune response. This includes vaccines and the like. The composition may be formulated for various forms of administration such as injection
10 (intraperitoneal, subcutaneous, intramuscular or intramammary), orally, nasal spray, skin patch or the like.

The term "a peptide capable of eliciting an immune response" refers to any peptide which is
15 immunogenic *per se* or is capable of inducing an immune response once administered in the composition. Preferably the peptide of the first aspect of the invention is used in the composition, but other peptides, such as bacterial and viral antigens, are also
20 contemplated.

Those skilled in the art will be familiar with methods which may be employed to produce the immunogenic composition. The composition may include other components such as other active ingredients, drugs or
25 adjuvant as desired.

In a seventh aspect the present invention provides a method of delivering to an animal a peptide capable of eliciting an immune response, comprising the step of administering said peptide together with an
30 effective amount of an oil comprising:

20-70%	octadec - 9 - enylglyceryl ether
3-25%	1 - hexadecylglyceryl ether
1-15%	hexadec - 7 - enylglyceryl ether
5	1.5-20% octadecyl glyceryl ether
	1-15% eicosa - 9 - enylglyceryl ether
	1-25% lecithin
	1-25% DL alpha tocopherol acetate
10	0-3% 1,2,5-dihydroxycholecalciferol
	0-5% vitamin A
	0-40% non-mineral oil

15 The peptide is preferably emulsified with an effective amount of the oil.

The term "an effective amount of oil" refers to an amount of oil which will be effective in enabling the peptide to elicit an immune response, particularly where the peptide is not immunogenic by itself or only induces 20 low levels of immunity. Such an amount will generally be about 50 to 80% of the total volume of the composition, preferably 60-70% of the total volume, more preferably about 66 to 67% of the total volume of the composition.

25 In an eighth aspect the present invention provides a method of modulating one or more hormonal responses in an animal, comprising the step of administering to said animal a hormone-modulating effective amount of the peptide of the first aspect of the invention or the IRM of the second aspect of the 30 invention.

The hormonal responses include endocrine and/or paracrine responses.

35 The term "modulating one or more hormonal responses" refers to altering, adjusting or varying the hormonal responses in the animal concerned.

The animal may be any animal, preferably a vertebrate, more preferably a mammal. The term animal includes humans, ruminants, birds and reptiles.

Preferably the animal is a domestic or production animal
5 such as a pig, goat, camel, sheep, alpaca, llama, chicken, goose, duck, turkey, ostrich, emu, fish or other economically important animal.

Preferably the peptide administered is the peptide complex discussed above, preferably having more
10 than one antigen. More preferably the peptide is administered to the animal in the form of a pharmaceutical preparation, still more preferably, a vaccine formulation.

In a preferred aspect the invention relates to a
15 method of modulating the hormonal responses to one or more of somatostatin, gastrin, insulin, glucagon, prolactin, molitin, cholecystokinin, secretin, prostaglandins, IGF-I, IGF-II, growth hormone and thyroid hormones by administration of the peptide or IRM
20 of the invention.

In another preferred aspect the invention relates to a method of enhancing gastrointestinal function in an animal, comprising the step of administering an effective amount of a peptide based on
25 SSTR and/or IGFBP to said animal.

The term "enhancing gastrointestinal function" refers to promoting digestion of and absorption of key metabolic substrates.

In another preferred aspect the invention
30 provides a method of increasing anabolism and/or body weight in an animal, comprising the step of administering an effective amount of a peptide based on SSTR and/or IGFBP to said animal.

Preferably the peptide is that of the invention
35 described earlier.

In another preferred aspect the invention provides a method of increasing circulating insulin, IGF-I and/or IGF-III in an animal, comprising the step of administering an effective amount of a peptide based 5 on SSTR and/or IGFBP to said animal.

In another preferred aspect the invention provides a method of suppressing gastric enzymes in an animal, comprising the step of administering an effective amount of a peptide based on SSTR to said 10 animal.

Preferably the peptide is that of the invention described earlier. More preferably the peptide is that based on SSTR.

In another preferred aspect the invention 15 provides a method of increasing fibre production and optionally further altering the proportion of secondary to primary follicles in a fibre-producing animal, comprising the step of administering an effective amount of a peptide based on SSTR and/or IGFBP to said animal.

20 Preferably the peptide is that of the invention described earlier.

The term "a fibre producing animal" refers to any animal which produces a useful fibre such as wool or the like and includes sheep, goats, llamas and alpacas.

25 In another preferred aspect the invention provides a method of increasing milk production in a milk-producing animal, comprising the step of administering an effective amount of a peptide based on SSTR and/or IGFBP to said animal.

30 Preferably the peptide is that of the invention described earlier.

The term "milk producing animal" refers to any animal which produces milk either for human consumption or for suckling its young, and includes cows, goats, 35 sheep, camels and the like.

In another preferred aspect the invention provides a method of decreasing the activity of the c-fos gene and/or increasing the activity of the c-jun gene in an animal, comprising the step of administering 5 an effective amount of a peptide based on SSTR to said animal.

Preferably the peptide is that of the invention described earlier.

In another preferred aspect the invention 10 provides a method of altering calcium metabolism in an animal, comprising the step of administering an effective amount of a peptide based on SSTR to said animal.

Preferably the peptide is that of the invention 15 described earlier.

Without wishing to be bound by theory, it appears that administration of a peptide based on SSTR affects the activity of the c-fos and c-jun genes and therefore calcium metabolism. This results in changes in 20 muscle function. For example animals treated with the peptide have shown improved water holding capacity in the muscle tissue. The improvement is in the order of 20%.

In a related aspect the invention provides a 25 method of stimulating an immune response to a hormone, carrier protein, binding protein or a hormone receptor in an animal wherein said immune response modulates hormone activity, said method comprising the step of administering an immune response-inducing effective 30 amount of the peptide of the first aspect of the invention to said animal.

In another related aspect the invention provides a method of stimulating an antibody response to a hormone, carrier protein, binding protein or hormone 35 receptor wherein said response modulates hormone or

receptor activity in an animal and wherein said antibody response results in antibodies being secreted on the mucosa of the animal and/or in the milk of said animal, said method comprising the step of administering to said 5 animal an antibody stimulating effective amount of the peptide of the invention.

Preferably the mucosa onto which antibodies are secreted is the lung, mammary, gastrointestinal and/or urogenital mucosa.

10 In a further aspect, the invention provides a kit comprising the novel peptides or molecule of the invention, optionally further comprising the immuno-adjuvant oil of the invention.

15 DETAILED DESCRIPTION OF THE INVENTION

The invention will now be described with reference to the following non-limiting Figures and Examples.

20 Figure 1 is a diagrammatic representation of multiple antigen peptide (MAP) showing 7 branching lysine with peptide antigens.

Figure 2 is a diagrammatic representation of MAP showing 16 branching lysine with 36 peptide antigens.

25 Figure 3 is a graphic representation of live weights of pigs during pregnancy and lactation in Example 6.

Figure 4 is a graphic representation of live weights of piglets in Example 6.

30 Figure 5 is a graphic representation of milk produced by cows in Example 9.

Figure 6 is graphic representation of live weight of chickens in Example 10.

Figure 7 is a graphic representation of live weight of pigs in Example 11.

Figure 8 is a graphic representation of live weight of chickens in Example 14.

Figure 9 is a graphic representation of live weight of male pigs in Example 15.

5 Figure 10 is a graphic representation of live weight of female pigs in Example 15.

Figure 11 is a graphic representation of the live weight of pigs in Example 16.

10 Figure 12 is a graphic representation of the net, overall live weight gain of sows in Example 17.

Figure 13 is a graphic representation of the live weight of the sows in Example 17.

Figure 14 is a graphic representation of the live weight of the piglets in Example 18.

15 Figure 15 is a graphic representation of the live weight of the twin lambs in Example 19.

Figure 16 is a graphic representation of the yield of milk from the ewes in Example 19.

20 Figure 17 is a graphic representation of the live weight of the cows in Example 20.

Figure 18 is a graphic representation of the live weight of the calves in Example 20.

Example 1 Preparation of the peptides

25 Peptides were synthesised using a solid phase automated peptide synthesiser (for example Advanced ChemTech ACT Models 396, 348 or 90).

30 The purity of these peptides is determined by analytical HPLC and an amino acid analyser. The quality of the peptides of this invention was further supported by amino acid composition analysis. The peptides were then lyophilised and stored at -20°C.

Example 2 Enzyme-linked immunosorbent assay

An enzyme-linked immunosorbent assay (ELISA) was developed to measure anti-SSTR or anti-IGFBP antibodies in biological fluids; plasma, fat-free colostrum, milk, 5 and gastric mucosa. Multi-well plates were coated with 100 μ L of phosphate buffered saline (PBS; pH 7.4) containing 5 μ g mL^{-1} of a complex of SSTR and/or IGFBP antigens and ovalbumin (Sigma Chemical Co., St Louis, U.S.A.) for 16 hours at 4°C. The antigen-coated plates 10 were then rinsed three times with PBS containing 5% (w/v) skim milk ("Coffee Mate"; Carnation, Nestle, Sydney, Australia). To prevent the incidence of non-specific binding, the remaining absorbent sites were blocked by dispensing 100 μ L of PBS plus 5% skim milk 15 solution per well for 2 hours at room temperature. At the cessation of the "blocking" period (2 hours) and subsequent steps, the plates were washed three times with a solution of PBS containing 0.1% (v/v) Tween-20 (PBST). To each well was added an aliquot of 100 μ L of 20 diluted sample (1/400 v/v; plasma, fat-free colostrum or gastric mucosae in PBST) and the plates were incubated for a further 2 hours at room temperature. Next, an aliquot of 100 μ L of goat anti-porcine IgG -Fc fragment 25 or goat anti-porcine IgA -Fc fragment (1/400 (v/v) in PBST; Nordic Immunological Laboratories, Tilburg, The Netherlands) was added to each well and plates were incubated for a further 2 hours at room temperature. The final incubation for each well was with 100 μ L of a 1/400 dilution of horseradish peroxidase-conjugated 30 rabbit anti-goat IgG -H+L fragment (Nordic Immunological Laboratories, Tilburg, The Netherlands) in PBST plus 5% skim milk, for 2 hours. Prior to the addition of the substrate, the final wash consisted of two washes with PBST then one wash with distilled water. The plates

- 30 -

were developed using 100 μ L of substrate [1 mM 2,2'-azino-di (3-ethylbenzthiazoline sulphonate) crystallised diammonium salt (ABTS; Sigma Chemical Co., St Louis, U.S.A.) and 2.5 mM H₂O₂ in 10 mL citrate phosphate buffer (0.1 M citric acid, pH was adjusted to 4.2 with 0.5 M Na₂HPO₄)] per well and absorbances were read after 30 minutes and 60 minutes with a Titertek MC plate reader at 450 nm. Each sample was tested in duplicate and both positive and negative controls were included 10 for each ELISA plate.

15 Titres of anti-SSTR or IGFBP antibodies in the plasma, colostrum, milk and gut mucosa were expressed as the ratio of the optical density (OD) reading for positive control sample relative to the OD reading for the test sera (Steward and Lew, 1985; Reynolds et al., 1990). This ratio was multiplied by the dilution factor of each sample to establish relative quantities of each isotype produced.

20 Antibody titre = (OD₄₅₀ test sera) \times (OD₄₅₀ standard)⁻¹ \times sample dilution⁻¹

The avidities of anti-SSTR or IGFBP antibodies were determined using scatchard plot analyses as outlined by Holst et al., (1992a).

25 Example 3 Preparation of the peptide complex

It is preferred that a multiple antigen peptide (MAP) system is employed to present/carry the antigens to the immune system. This approach to prepare peptide immunogens of relatively small molecular weight 30 overcomes the ambiguity of conventional carrier systems (i.e KLH, BSA thyriodglobulin etc.). The MAP approach produces chemically defined peptide antigens with a high degree of homogeneity. As a consequence immunogens prepared by the MAP approach elicit high and uniform

antibody response to the immunogen in immunised animals. As such, the MAP approach to presenting the antigens described in the present application is particularly suitable for eliciting a uniform and site-specific 5 antibody response to the desired antigens.

Historically the MAP system consists of an oligomeric branching lysine core, usually composed of three or seven lysines, and four or eight copies of dendritic arms of peptide antigens (see Fig 1). 10 However, the MAP system employed in the present application consists preferably of 18 to 20 branching lysine core giving rise to 36 to 40 copies of dendritic arms of the peptide antigens (see Fig 2). Since each peptide arm may consist of 5-20 amino acids, the overall 15 appearance of the MAP system is of a macromolecule with a high density of surface peptide antigens and a molecule weight exceeding 40,000.

The MAP system can be used to present a single antigen alone or any combination of antigens thereof. 20 Furthermore, the antigen/carrier system displays no apparent biological activity, even if injected actively.

The MAP system described in the present application was synthesised using a solid phase 25 automated peptide synthesiser (for example Advanced ChemTech ACT Models 396, 348 or 90).

The MAP/antigen is then suspended (ideally emulsified) into a non-inflammatory delivery vehicle or immunostimulator (coded as NSB-050). In this form the 30 product is administered usually by intraperitoneal or subcutaneous injection. The product may also be injected intramammarily, intramuscularly, or delivered orally. Following subcutaneous or intraperitoneal injection the emulsion rapidly is taken up by the 35 lymphatic system, and presented to the immune system.

At this point there is attachment of the various antigens to receptor sites on the processing cell of the immune system, resulting in the production of the specific antibodies of high titre and affinity.

5

Example 4 The Delivery Vehicle

A clear oily liquid has been identified as particularly useful in developing antibodies which are secreted on the epithelial surfaces of the lung, 10 gastrointestinal and urogenital tracts, the mucosa of the mammary and thus subsequently the colostrum and milk of animals immunised actively. Furthermore, the delivery system (NSB-050) is a particularly effective immunostimulator when attempting to elicit an immune 15 response to a number of different antigens concurrently.

In general, the oil has the following composition:

diacylglycerol ethers	30-50%
triacylglycerols	40-70%
20 polar lipids	10-15%
free fatty acids	>2%
hydrocarbons	>2%
wax esters	>2%

Specifically, the oil is of the following 25 typical analysis:

octadec-9-enylglyceryl ether	45% (20-70)
1-hexadecylglyceryl ether	11% (3-25)
hexadec-7-enylglyceryl ether	5% (1-15)
octadecyl glyceryl ether	7% (1.5-20)
30 eicosa-9-enylglyceryl ether	5% (1-15)
lecithin	13% (1-25)
DL alpha tocopherol acetate	7% (1-25)
1,2,5-dihydroxycholecalciferol	1% (0-3)
Vitamin A	1% (0-5)

Non-mineral oil (vegetable or animal origin) 5% (0-40)

The delivery vehicle, except for lecithin and non-mineral oil (vegetable or animal origin) are oils extracted from the livers of deep sea sharks, specifically the livers of the Pacific sleeper shark (*Somniosus pacificus*) and the Plunket shark (*Centroscymnus plunketi*). The oils are recovered from the livers of these sharks at less than or equivalent to 125°C and at a pressure less than or equivalent to 666.6 Pa.

Ideally, the livers are collected fresh from these sharks which are preferred because the oils are devoid of or contain minimum levels of hydrocarbons and wax esters. The excised livers are washed in fresh sea or tap water, and then macerated. The macerated mass is allowed to stand at room temperature (ideally 25°C) for 3 hours, after which the oil is decanted. Clarification of the oil occurs firstly by centrifugation, then by washing with water, followed by a deproteinisation step with bentonite, or similar material. Following a further washing of the oil, it is then stored at 4°C storage for a few weeks to sediment out any winterable material. The clear supernatant is then decanted, mixed with the lecithin emulsifier, and with any of the oil soluble vitamins desired to form the oily delivery vehicle. It is stored in appropriate containers and treated with nitrogen gas to prevent oxidation.

Example 5 Preparation of the Vaccine

The constructed protein molecule was dispersed in phosphate buffered saline (pH 7.4) by use of ultrasonic agitation. (It is helpful to the performance of the immunogen if the antigen is not soluble in the aqueous phase, and if the protein is dispersed into

- 34 -

single molecules in the liquid). The antigen was mixed preferably in saline (aqueous phase) and emulsified with the oil phase at the rate of 2 parts of oil to 1 aqueous part to produce a stable water-in-oil emulsion. Ideally 5 the concentration of antigen in the aqueous phase is such that a 3 ml dose of emulsion contains 100 µg of antigen macromolecule. Generally the amount of oil in the dose is 2ml (about 66.6% of the total volume of the vaccine), the remaining 1ml accounts for the aqueous 10 phase containing phosphate buffered saline and antigen.

Example 6 Administration of Vaccine

The vaccine may be injected by the intraperitoneal, or subcutaneous routes (for preference), but may also be 15 administered via intramammary, intramuscular, or oral routes. Booster injections (preferable two) were generally administered within given 2 weeks or longer after the primary vaccination.

20 Example 7 Administration of peptides SEQ ID NO:12,
 14, 21, 22, 36, 38, 42 & 44 to pigs

Gilts

Thirty primiparous pigs (Landrace x Large White) were mated naturally to cross-bred boars. Approximately 25 10 days prior to parturition, gilts were transferred to farrowing crates in an enclosed shed maintained at approximately 24°C and lit artificially by fluorescent lighting with a 12 hour dark/light cycle.

30 *Piglets*

In an attempt to minimise the effect of litter size on milk yield and the subsequent growth of sucking piglets (King *et al.*, 1993), the number of piglets per litter was standardised to eight.

Experimental procedures

Prior to mating the gilts were divided randomly into six groups of five such that those gilts in group 1 received placebo injections and pigs in groups 2, 3, 4, 5 and 6 were immunised against SSTR 1 (peptide #12 and 14), SSTR 2 (peptide #21 and 22), SSTR 3 (peptide #26 and 38), SSTR 4 (peptide #42 and 44) and SSTR 5 (peptide #48 and 50) respectively. During pregnancy both 10 immunised and non-immunised gilts were injected subcutaneously in the neck with 3 ml of the corresponding vaccine (SSTR 1 (peptide #12 and 14), 2 (peptide #21 and 22), 3 (peptide #36 and 38), 4 (peptide #42 and 44) and 5 (peptide #48 and 50) coupled to the 15 MAP and emulsified in NSB-050) at c. 40, 65 and 90 days after mating.

Liveweights of the gilts/sows were measured each week from mating to parturition, thence at weaning which occurred at three weeks *post partum*. Immediately after 20 parturition, birthweights of piglets were recorded and thereafter liveweights were measured at weekly intervals until weaning, thence at five weeks of age.

On day three *post partum* eight piglets passively immunised via the dam and a further eight control 25 piglets were modified surgically to determine gastric acidity, portal blood flow, plasma hormones and MCA in response to intravenous infusions of pentagastrin at the rate of 10 $\mu\text{g kg liveweight}^{-1}$ hour. A further eight piglets from each group were treated similarly on day 21 30 *post partum*.

Results

Effects of immunisation on sows

There were no obvious lesions at the sites of injection or any detrimental side effects which may have 5 been attributed to the vaccination regime imposed for immunised or control sows.

Liveweights

Sows

10 As depicted in Figure 3 those gilts immunised against SSTR 2 (peptide #21 and 22), SSTR 3 (peptide #36 and 38), and SSTR 5 (peptide #48 and 50) antigens were significantly heavier at parturition and tended to lose more weight during the subsequent lactation than 15 corresponding control sows.

Piglets

The total numbers of piglets (dead or alive) and the number of males and females born per litter did not 20 differ significantly for immunised or control sows.

Piglets from sows immunised against SSTR 2 (peptide #21 and 22), SSTR 3 (peptide #36 and 38), and SSTR 5 (peptide #48 and 50) were significantly heavier at birth relative to those piglets from control sows or 25 sows immunised with SSTR 1 and 4 (see Table 2).

Data for the growth of piglets are summarised in Table 2 and Figure 4. After three weeks from birth, piglets from sows immunised with SSTR 1 (peptide #12 and 14), SSTR 2 (peptide #21 and 22), SSTR 3 (peptide #36 and 38), SSTR 4 (peptide #42 and 44) and SSTR 5 (peptide #48 and 50) during pregnancy grew significantly faster 30 than corresponding piglets from non-immunised dams. This difference in growth rates of piglets from immunised sows was maintained throughout the experiment

such that, at five weeks of age, piglets from immunised dams were some 20-30% heavier than those piglets from corresponding control sows.

The above differences were apparent for piglets 5 of both sexes throughout the period of the experiment. Thus, male and female piglets of immunised sows grew significantly faster ($P < 0.01$) than corresponding piglets from control sows.

10 *Antibodies in blood, colostrum and gut scrapings*

Mean titres of antibodies to SSTR 1 (peptide #12 and 14), SSTR 2 (peptide #21 and 22), SSTR 3 (peptide #36 and 38), SSTR 4 (peptide #42 and 44) and SSTR 5 (peptide #48 and 50) in the colostrum of immunised and 15 control sows are shown in Table 3. Titres of anti-SSTR antibodies in the plasma and gut scrapings of piglets, collected prior to and after the gastric infusions studies on days three and 21 are summarised in Table 3. Throughout the study, antibodies to SSTR were not 20 detected in the colostrum of non-immunised sows or in the plasma and stomach mucosa of piglets sucking control dams. In contrast, high titres of SSTR antibodies were detected in the colostrum of all immunised sows, as well 25 as in the plasma and mucosal scrapings of piglets sucking immunised dams at both three and 21 days post partum.

30 Titres of anti-SSTR IgG antibodies were significantly greater ($P < 0.01$) than levels measured for anti-SSTR IgA antibodies in the colostrum collected from immunised sows at, or near, the time of parturition. Similar differences in the levels of IgG relative to IgA anti-SSTR antibodies were recorded in the mucosa scrapings of piglets sucking immunised dams; this was more apparent for piglets at 21 than at three

days of age. In contrast, no significant differences were measured for titres of IgG and IgA anti-SSTR antibodies in the plasma of immunised piglets on days three and 21. Furthermore, levels of IgG antibodies 5 measured in the stomach mucosa did not differ significantly ($P > 0.10$) from levels detected in plasma of immunised piglets, at both three and 21 days post partum. However at all times, titres of anti-SSTR IgA antibodies in the plasma were significantly ($P < 0.05$) 10 greater than levels detected in the gastric mucosa for those piglets from immunised sows.

Feed intakes of sows

Throughout the period from parturition to 15 weaning, immunised and control sows consumed all offered feed. Thus, the efficiency of utilisation of food for growth of sucking piglets and/or for milk production was significantly greater ($P < 0.05$) for immunised than control sows.

20

Hormones and gastric function

Plasma samples collected from piglets over the three week period until weaning showed that there was no significant difference in the concentrations of growth 25 hormone, thyroid hormones or glucagon for piglets sucking immunised or control sows. However, levels of circulating concentrations of insulin and IGF I and II were significantly greater for immunised piglets relative to corresponding control piglets.

30

The level or amount of gastric acid secretion following pentagastrin stimulation was observed to be retarded significantly for those piglets sucking immunised than control dams. Furthermore, the activity of key gastric enzymes were suppressed in these piglets.

The results from these studies suggest that antibodies which block the SSTR 1 through to 5 alter gut function and thereby improve digestion.

5 Example 8 Administration of peptides SEQ ID NO: 18,
 20, 36, 38, 48 & 50 to sheep.

Twenty pregnant merino sheep were selected randomly at 40 days of pregnancy and divided into two groups of ten; immunised and control. During pregnancy 10 immunised ewes were administered subcutaneously in the neck a 3 ml emulsion of the antigen in NSB-050 at c. 90, 110 and 132 days of pregnancy. Placebo injections were administered to control ewes at the corresponding times. The antigens used for immunisation comprised of the SSTR 15 2 (peptide #18 and 20), SSTR 3 (peptide #36 and 38) and SSTR 5 (peptide #48 and 50) coupled individually to the MAP system and were administered concomitantly.

At weaning (3 months *post partum*) there was no significant difference in liveweights for immunised 20 relative to corresponding control ewes. Liveweights of those lambs sucking immunised dams were some 20% heavier than those sucking control ewes.

The yields of wool were approximately 10% greater for immunised than control ewes during pregnancy 25 and subsequent lactation. Furthermore, the yields of wool for lambs consuming colostrum/milk from immunised dams was improved by some 20% than corresponding control lambs. In addition the wool harvested from immunised lambs was significantly finer than that collected from 30 control lambs. The changes in wool characteristic has been postulated to be attributed to improved nutritional status of those lambs sucking immunised dams leading to greater populations of secondary and primary follicles (see Table 4).

Example 9 Administration of peptides SEQ ID NO:18
20, 36, 38, 48 & 50 to cattle.

Twenty pregnant beef heifers were selected from
5 a grazing herd and allocated to two groups of ten;
immunised and control. Immunised cows were injected
subcutaneously in the neck with a complex of SSTR 2
(peptide #18 and 20), SSTR 3 (peptide #32 and 34) and
SSTR 5 (peptide #48 and 50) antigens coupled to the MAP
10 system emulsified in NSB-050 at c. 5, 7 and 8 months of
pregnancy. The remaining ten cows were injected with
placebo injections administered subcutaneously in the
neck at the corresponding times. Calves from immunised
cows were significantly heavier at birth (38 v 46 kg;
15 P<0.05) than corresponding calves from non-immunised
cows. During a ten week period calves sucking dams
immunised against SSTR 2 (peptide #18 and 20), SSTR 3
(peptide #36 and 38) and SSTR 5 (peptide #48 and 50)
grew significantly faster (by some 10-15%) than calves
20 from control cows.

Example 10 Administration of peptides SEQ ID NO: 18,
20, 36, 38, 48 & 50 to sheep.

Twenty-four crossbred ewes (Merino x Dorset
25 Horn) were allocated to two treatment groups; immunised
(n=12) and control (n=12). Immunised ewes were injected
subcutaneously in the neck with a complex of SSTR 2
(peptide #18 and 20), SSTR 3 (peptide #36 and 38) and
SSTR 5 (peptide #48 and 50) peptides and MAP emulsified
30 in NB 050, the remaining ewes received placebo
injections. Ewes were administered corresponding
injections at approximately 90, 110 and 130 days of
pregnancy. Over a six week period from the time of
parturition immunised ewes produced significantly more
35 milk (20%) than non-immunised ewes (see Figure 5). The

- 41 -

increase in milk yield observed for immunised ewes could not be accounted for by increased appetite, thus immunised ewes utilised their feed more efficiently than control ewes.

5

Example 11 Administration of peptides SEQ ID NO: 27,
29, 36, 38, 48 & 50 to chickens.

Forty day old chickens were allocated randomly two treatment groups; immunised and control. Immunised 10 birds were injected intraperitoneally at one day age and subsequent booster vaccinations were administered orally at 7 and 14 days of age with 20 µg of a complex of SSTR 2 (peptide #27 and 29), SSTR 3 (peptide #36 and 38) and SSTR 5 (peptide #48 and 50) coupled to the MAP system 15 emulsified in NSB 050. Control birds received placebo injections at the corresponding site and time.

Over the first 4 weeks after the initial vaccination immunised birds were significantly heavier than corresponding control birds such that at the 20 cessation of the experiment immunised birds were some 24% heavier than control birds (see Figure 6).

At 21 and 42 days of age a representative proportion (n=5) of birds from each group were selected randomly and euthanised for muscle analysis. The 25 patagialis muscle was dissected from the each of the birds. The yield of wet muscle collected from immunised birds was recorded to be some 23% and 30% heavier than control birds at 21 and 42 days of age respectively. Although the mass of the patagialis muscle for immunised 30 birds was observed to be heavier than corresponding control birds, the total yield of RNA per gram of muscle tissue was significantly less for immunised relative to control birds. When identical amounts of recovered DNA from the patagialis muscle of both groups of birds were

- 42 -

titrated for the *c-fos* and *c-jun* genes it was observed that the copy numbers of the *c-fos* gene was suppressed significantly and *c-jun* gene was increased relative to control birds.

5 It is apparent from the results of the present study that vaccination against SSTR 2 (peptide #27 and 29), SSTR 3 (peptide #36 and 38) and SSTR 5 (peptide #48 and 50) increased liveweight gain of immunised birds. Furthermore, it is evident that intracellular mechanisms 10 of key muscle systems were altered significantly following immunisation. The immunisation procedures resulted in the suppression of the transcriptional regulator gene *c-fos* and amplified activity of *c-jun*. The changes in the activity of these genes observed for 15 immunised relative to control birds is hypothesised to be associated with altered transcription of protein to protein binding relationships resulting in changes in the signal transduction pathways and thus increased calcium metabolism.

20

Example 12 Administration of peptides SEQ ID NO: 21,
23, 36 & 38 to pigs

Twenty six week old cross-bred male pigs were allocated randomly to two treatment groups; immunised 25 and control. Pigs were injected subcutaneously in the neck with either a mixture of SSTR 2 (peptide #21 and 23), SSTR 3 (peptide #36 and 38) and SSTR 5 (peptide #48 and 50) antigens coupled to the MAP system emulsified in NSB 050 or placebo injections at 42, 63 and 84 days of 30 age. At the cessation of the experiment (20 weeks of age) pigs immunised against SSTR were significantly heavier (91.5 v 83.5 kg) than corresponding control pigs (see Fig 7).

- 43 -

Example 13 Administration of peptides SEQ ID NO: 54
to 57 to rats

Twenty laboratory rats were allocated randomly to two treatment groups immunised and control.

5 Immunised rats were injected subcutaneously in the medial thigh with a 3 ml emulsion containing 100 µg of a mixture of IGFBP 1 (peptide #47), IGFBP 2 (peptide #55), IGFBP 3 (peptide #56) and IGFBP 4 (peptide #57) antigens described in the present patent coupled to the MAP 10 system suspended in NSB 050. Control rats received placebo injections administered subcutaneously in the medial thigh. The rats were administered three booster injections at intervals of 21 days with the corresponding vaccines. Blood samples were collected 15 over the period of the study for antibody titres and concentrations of key metabolites and hormones. Over the study those rats immunised with the IGFBP antigens grew significantly faster and the concentrations of glucose (2.5 v 4 mM) and insulin (20 v 30 ng/ml) were 20 suppressed relative to corresponding control rats. The above vaccination regime may have profound effects on glucose metabolism in diabetes syndromes Type I and II.

Example 14 Administration of the Peptide SEQ ID NO:1
(LCFWKTC to chickens

The peptide and delivery vehicle is hereinafter referred to as FEEDMIZA

Protocol

30 Freshly hatched 1 day old chicks were allocated randomly into the following groups.

Group A non-immunised (n=30)

Group B immunised subcutaneously (n=30)

- 44 -

Group C immunised intraperitoneally (n=30)

5 Immunisations took place on the day of hatching and at 21 days of age. The FEEDMIZA dosage was 80 μ g of peptide in 0.1ml of emulsion.

At 49 days, animals in each experimental group were sacrificed. In addition to the collection of blood bile and gut scrapings were collected for subsequent antibody assay.

10

Results

15 The heaviest mean liveweights of the chickens at the end of the experiments were recorded. For Group C, the weights were 2.19 ± 0.057 kg. Mean liveweight was 2.07 ± 0.049 kg and 1.95 ± 0.047 kg for Group B and A respectively. The differences between each group were statistically significant ($P<0.05$). The chickens which were immunised by the intraperitoneal route were approximately 12.3% heavier than the non-immunised 20 birds. Those immunised by the subcutaneous route were an average of 7.2% heavier than the non-immunised birds. Antibodies to the FEEDMIZA antigen were detected in 100% and 60% of the samples of bile obtained from Group C and Group B respectively. No antibodies to the antigen 25 could be detected in the bile of the birds in Group A. Antibodies were detected in gut scrapings of 100% of the Group C birds, 50% of the Group B birds, and in none of the Group A birds.

30 Antibodies were detected in the blood of 100% of the birds in Group B, in 40% of the birds in Group C, and in none of the birds in Group A.

Conclusions and Discussion

A significant increase in liveweight at slaughter was observed following immunisation with the FEEDMIZA preparation, with the heaviest group being 5 those which had received the vaccination via the intraperitoneal route. It is potentially of significance that all of the chickens tested from the group which was immunised intraperitoneally showed evidence of antibody in the bile and gut scrapings, but only 40% of them 10 showed antibodies in the blood.

In contrast the chickens from Group B which had gained significantly more weight than the non-immunised birds, but significantly less than the birds which had been immunised by intraperitoneal injection, all showed 15 antibodies in the blood, but only half of them showed antibodies in the bile and gut scrapings.

This suggests that the birds which had been immunised by the intraperitoneal route had a immune response which differed from those birds which had been 20 vaccinated by the subcutaneous route. The intraperitoneal immunisation had stimulated outpouring of antibody via the bile (secreted antibody) onto the surface of the intestines. It is noted that there are many receptors for the hormones targeted by the FEEDMIZA 25 in the mucosal surface of the intestine, and that these receptors might be more amenable to, or available to antibody blocking than antibodies circulating in the blood.

This experiment has highlighted that 30 immunomodulation which relies upon the measurement of high levels of antibody to specific hormones in the blood may be laying an emphasis on the wrong measurement. If only blood samples had been collected in this experiment to monitor immune stimulation, it would 35 be arguable that there had been no immune stimulation in

- 46 -

the intraperitoneal-immunised birds because no circulating antibodies could be measured. However, the presence of the antibodies in bile and gut scrapings indicated otherwise. It is noted that the birds in the 5 group with 100% positive incidence of antibodies had the highest liveweight at slaughter, and the group with approximately 50% of the birds showing antibodies in the bile or gut scrapings performed midway between the two groups, while the non-immunised group with no gut or 10 bile antibodies showed the lowest weights.

Example 15 Administration of Peptide SEQ ID NO:1 to
Pigs

Protocol

15 The piglets from 12 litters were weaned at 4 weeks of age and randomised into 4 treatment groups, each of which contained 12 male and 12 female piglets. Each piglet was individually eartagged and weighed. The treatment groups were:-

20

Group A Control group- placebo injections of delivery vehicle

Group B Immunised by the subcutaneous route

Group C Immunised by the intraperitoneal route

25 Group D Immunised by the intramuscular route

The antigen used in the following experiments was the identical antigen to that used in Example 14. The micro-protein was constructed in an organic 30 chemistry laboratory. It was maintained at -20°C until it was dissolved in phosphate buffered saline at pH=7 (PBS) and then emulsified into the oily adjuvant just prior to use on the pigs.

All doses of vaccine used in the experiments was 3ml of the emulsion which contained 80ug of antigen. This dose was chosen arbitrarily, and was persisted with because success had been obtained at that rate.

5 The immunised groups received FEEDMIZA containing 80 μ g of antigen. The placebo group received 3ml of emulsion devoid of the antigen. Pigs were injected at 5, 8 and 12 weeks of age.

10 The pigs were reared in conventional weaning, growing and finishing pens. They were offered weaner, grower and finisher feeds *ad libitum*.

The experiment ran until the pigs reached 161 days of age (21 weeks). Pigs were individually weighed at 4, 8, 10, 12, 15, 16 and 21 weeks of age.

15

Results

The liveweights at 21 weeks of age, and the average daily liveweight gains of the various treatment groups are presented in Table 5 (the males) and Table 6 (the females).

Figs. 9 and 10 show the weights of the male and female pigs respectively at different ages during the experiment.

25 *Discussion*

The heavier weights of the pigs at 21 weeks of age which had been immunised by the subcutaneous route compared with the placebo injected pigs (21.69% for the male pigs, and 13.04% for the female pigs) was 30 statistically significant. From Figs. 9 and 10, it is evident that there was no detectable trend in improved daily liveweight gains for the male pigs until around 12 weeks of age. At 6 weeks of age the pigs immunised by the intramuscular and intraperitoneal routes were

significantly lighter than the subcutaneously immunised or placebo injected groups. However, by 10 weeks of age there were no significant differences between the weights of any of the groups.

5 In the case of the female pigs a similar trend was observed, except that the placebo pigs were significantly heavier than all other treatment groups at 6 weeks of age (2 weeks after the first immunisation/injection). At 10 weeks of age the group which had been
10 immunised subcutaneously were, like their male counterparts of similar weight to the placebo group, and significantly heavier than the group immunised intramuscularly and intraperitoneally. At 12 weeks of age all of the female treatment groups were
15 approximately of similar weights, a phenomenon which had occurred apparently some weeks earlier with the male pigs.

It is concluded that immunisation of pigs with FEEDMIZA vaccine, especially via the subcutaneous and
20 intraperitoneal routes has produced stastically significant responses in both male and female pigs, with the benefit being measured primarily over the last 6-8 weeks period of the test.

25 Example 16 Effects of SRIF and Peptide SEQ ID NO:1 in Gilts

This experiment was designed to measure the effects of vaccinating pregnant gilts with FEEDMIZA by the subcutaneous route during first pregnancy.
30 Opportunity was taken to compare any response to FEEDMIZA with response to a SRIF-conjugate vaccine delivered in the same delivery vehicle as peptide No.1. For that comparison the quantity of antigen was standardised at 100ug of SRIF in the SRIF-conjugate, and
35 100ug of the FEEDMIZA antigen.

Protocol.

Twenty four Landrace X Large White female hybrid gilts were selected, mated and held in 5 conventional dry sow stalls. They were randomly assigned to 3 treatment groups, viz:

Group A non-immunised controls
Group B immunised with FEEDMIZA
10 Group C immunised with a SRIF-conjugate

The gilts were immunised by subcutaneous injection of 3ml of the relevant antigen at the neck on the day of mating.

15 The animals were held in conventional single dry sow stalls. At 30 days of pregnancy the treatment groups were reduced to 5 confirmed pregnant animals per treatment group. Subsequent vaccinations were performed at weeks 6, 9 and 12 of pregnancy. Each gilt was fed 20 3kg of feed (Breedmore sow ration, Barastoc, Melbourne) each day from mating until farrowing. Each animal was weighed at mating, and at intervals of 3 weeks until farrowing.

25 *Results*

No untoward effects were noted with any of the immunisations, either by way of tissue reactions at the site of injection, or general effects on health or behaviour. The pigs which had been immunised with the 30 FEEDMIZA were substantially larger and were especially taller by mid-pregnancy.

The mean weights and standard deviations for the different treatment groups are presented in Figure 11. There were no statistical differences between any of 35 the groups up until 12 weeks of pregnancy. At the 12 and

- 50 -

15 weeks, animals in group B was stastically significantly heavier ($P<0.05$) than the non-immunised and the SRIF-immunised groups. There was a trend for the SRIF-immunised group to be heavier than the non-
5 immunised sows from 9 weeks of pregnancy, but at no point was this difference ever stastically significant (larger numbers of animals may have detected a stastistical difference)

At parturition the non-immunised sows had gained
10 an average of 60 kg per head, had eaten $115 \times 3\text{kg}$ of feed (345 Kg) and had converted that feed into liveweight gain at a ratio of 5.75:1. The FEEDMIZA-immunised sows had likewise consumed 345 Kg of feed, but had gained an average of 138 kg each during pregnancy,
15 at an efficiency ratio of 2.5:1. The SRIF-immunised group had gained an average of 75kg per head during the test period at an efficiency of converion of feed to liveweight gain ratio of 4.6:1.

20 *Discussion and Conclusions*

SRIF-conjugate vaccine was not successful in modulating growth stastically, but the FEEDMIZA preparation significantly improved liveweight gain. It is clear that the FEEDMIZA antigen and the SRIF-conjugate antigens are very different in the effect which they have on the modulation of growth of gestating sows.

Sows immunised with FEEDMIZA preparation were substantially better converters of feed to liveweight gain than were the SRIF immunised and the non-immunised sows.

This experiment has shown that antibodies which are actively generated to FEEDMIZA in gestating female pigs yet to reach mature body weight induce 35 modification to rates of liveweight gain, and feed

- 51 -

conversion ratios. It is noted that the pigs were fed measured quantities of feed on a daily basis, so no effect of these antibodies on voluntary feed intake would be influencing the results observed. The 5 modifications must come from either improved digestion, or absorption, or utilisation of the absorbed nutrients.

The four immunisations provided to these sows are probably more than is necessary to achieve successful immunomodulation. The regime was selected to 10 ensure high levels of antibody were present in the animals at all times since the objective was to measure the efficacy of antibodies in modulating the performance. A more practical regime might be vaccination at selection, at confirmation of pregnancy 15 and at transfer to the farrowing house. Further testing may indicate that less than 3 vaccinations per pregnancy produces acceptable results.

Example 17 Effects of SRIF and Peptide SEQ ID NO:1 on 20 Piglets

This experiment was a continuation of the trial of Example 16. It sought to observe the rate of liveweight gain of piglets during the lactation period up to weaning for piglets whose dams were immunised 25 during gestation with FEEDMIZA, or with a SRIF-conjugate vaccine, using piglets being reared by non-immunised dams as controls.

Protocol
30 Sows from Example 16 continued to be reared without any further immunisations or manipulations, with the exception that;

 a) daily feed offered was increased to 6kg per head from farrowing to weaning 21 days later.

- 52 -

b) 3 days after farrowing the number of piglets on each sow was reduced to 8 to ensure that each litter of pigs in the experiment was benefiting from the combined effects of the quantity of milk produced, and 5 ingested any antibodies that might be in them, without confounding influences of varying litter sizes, social interactions, and competition for teats. Sows were weighed at weaning.

Piglets were individually identified at birth, 10 and were weighed at birth, and each 7 days until weaning at 21 days of age. All piglets received a routine oral dose of broad spectrum antibiotic (Tribrissen Piglet Suspension, Intervet, Melbourne) at three days of age, as well as an intramuscular supplemental iron injection 15 Pignaemia, Intervet, Melbourne)

Water was available *ad libitum* to sows and piglets at all times.

Results

20 The mean liveweights of the non-immunised sows fell by 10.8 kg during the three weeks lactation period, compared with a similar 12 kg for the sows which had been immunised during pregnancy with the SRIF-conjugate vaccine. There was a statistically significant 25 ($P<0.05$) mean loss of 33.8 Kg for the group which had been immunised during pregnancy with the FEEDMIZ as shown in Figure 12.

The weights of the sows at farrowing and at weaning were:

- 53 -

	<u>Weaning weight (kg)</u>	<u>Farrowing weight (kg)</u>	<u>Weight loss</u>
5	157.6 ± 24.2	146.8 ± 33.3	6.8
	166.4 ± 26	154 ± 27.68	7.2
	219.8 ± 20.44	186 ± 18.05	15.4

- 54 -

The results are also represented in Figs. 13a and 13b.

Sows which were immunised with the FEEDMIZA vaccine were noted to have prolific milk production as evidenced by teats frequently leaking copious quantities of milk, especially during the first week of lactation.

Discussion and conclusions

Sows lost weight during the lactation phase irrespective of whether they had been vaccinated during pregnancy, or not. This is obviously a response to the demands of lactation which are not adequately met from the increased daily ration offered. However, the magnitude of the loss of weight of sows during lactation which had been immunised with FEEDMIZA during gestation, and which had so dramatically increased in liveweight during pregnancy as reported in the previous trial, was double that which was observed for either the non-immunised or SRIF-conjugate immunised sows. This is a dramatically different pattern from that observed with either of the two other treatment regimes as shown in Figure 13. One possible explanation for this dramatic loss of weight was that additional stimulation of lactation had been initiated by the anti-FEEDMIZA antibodies acting at the pituitary or mammary glands, or by suppression of normally present inhibitory mechanisms, or both. It was not possible in this experiment to measure the milk production of these sows, but observation of the udders suggested that large quantities of milk were being produced. Parallel studies in sheep have confirmed that in that species, immunisation with FEEDMIZA during pregnancy was associated with a measured 20% increase in output of milk during lactation. It is probable that immunisation with FEEDMIZA during pregnancy resulted in the

- 55 -

generation of antibodies in the animal for the 3 week period from farrowing to weaning, and were responsible, via direct or indirect means, for stimulating increased milk production, thereby creating physiological demand 5 upon the sow to repartition nutrients from retained reserves into milk production.

It appears that the FEEDMIZA antibodies are associated with improving the potential productive (liveweight gain or milk production) characteristics of 10 pregnant/lactating pigs. Since both of these functions involve the metabolism of calcium, carbohydrate and protein in particular, these results indicate that antibodies produced to the SRIF-conjugate were less potent in the terms of promoting liveweight gain than 15 were the anti-FEEDMIZA antibodies. It is hypothesised that immunisation with FEEDMIZA into gestating pigs results in increased efficiency of the normal metabolic pathways involving these key metabolites. Whether the effect of the antibodies is stimulatory, or whether it 20 occurs by removal of normal inhibitory mechanisms is not clear.

Example 18 Effects of SRIF and Peptide SEQ ID NO:1
Following Immunisation of Pre-Farrowing
25 Sows

This experiment sought to study the effects pre-farrowing immunisation of sows with SRIF-conjugate vaccine, or FEEDMIZA vaccine on the subsequent patterns of liveweight gain of their sucking piglets to weaning 30 at 3 weeks of age, and for the post-weaning period

The experiment monitored the piglets which were the subject of the previous experiment.

- 56 -

Protocol

The piglets (8 per litter) on each of the 5 sows in the treatment groups (non-immunised, SRIF-conjugate immunised and FEEDMZA-immunised) were individually eartagged for identification, and were weighed at birth, 5 7, 14, 21 days (the day of weaning) and 35 days of age (2 weeks post-weaning).

During lactation the piglets had ready access to a creep area which was warmed by an infra-red lamp, 10 water ad libitum and creep feed granules (Barastoc, Melbourne) for the period of 18-21 days of age. They had no access to their mothers feed during the period of lactation

At weaning each litter of piglets was placed in 15 a flatdeck weaning cage with 50% of the floor being bedding area, and 50% woven wire mesh. The cage was provided with a small silo feeder containing the same creep/weaner feed which had been offered to the piglets for the 3 days prior to weaning. Feed and fresh 20 drinking water were offered ad libitum.

Results

The mean birthweights of the piglets were:

25	i)	born to non-immunised sows
		1.22 ± 0.61 Kg
	ii)	born to SRIF-immunised sows
		1.40 ± 0.29 Kg
	iii)	born to FEEDMIZA-immunised sows
30		1.58 ± 0.21 Kg

The piglets born to the FEEDMIZA-immunised sows were statistically heavier ($P<0.05$) than those born to

- 57 -

the other groups (which were not statistically different from each other).

The liveweights of the piglets at weaning were:

5 i) piglets sucking from non-immunised sows
 6.05 ± 0.63 Kg
 ii) piglets sucking from SRIF-immunised sows
 7.32 ± 1.30 Kg
 iii) piglets sucking from FEEDMIZA-immunised sows
10 8.30 ± 1.13 Kg

The differences in the mean weights between each treatment group was statistically significant ($P<0.05$).

15 Liveweights of the piglets 2 weeks after weaning were:

i) piglets which had been sucking non-immunised sows
 7.58 ± 0.66 Kg
20 ii) piglets which had been sucking SRIF-immunised sows
 8.89 ± 1.33 Kg
 ii) piglets which had been sucking FEEDMIZA-immunised sows
25 10.62 ± 0.81 Kg

Each of these mean liveweights was statistically different from each other ($P<0.05$).

30 The mean liveweights of each of the treatment groups of piglets is presented in Figure 14.

Discussion and conclusions

35 Immunisation of pregnant sows with SRIF-conjugate antigen, or with FEEDMIZA resulted in increased rates of liveweight gain of piglets sucking

- 58 -

those dams compared with non-immunised sows. This suggests that immunomanipulation of animals for the purpose of increasing milk production is possible. Immunisation of pregnant sows with FEEDMIZA vaccine 5 produced statistically significantly heavier weights of piglets which sucked them for 3 weeks than was observed for piglets sucking either non-immunised, or SRIF-immunised sows at the observation points of birth, weaning and 2 weeks post-weaning. This observation 10 suggests that the process of immunomanipulation had been more effectively achieved with FEEDMIZA than with the SRIF-conjugate.

Example 19 Administration of Peptide SEQ ID NO:1 to
15 Sheep

Sheep have been the subject of numerous published attempts at immunomodulation with a variety of hormones. Sheep have many production characteristics that are similar to the pig production cycle, viz a 20 relatively short period of gestation, rapid rate of gain of the sucking young, and a relatively short period of lactation. They are relatively easy animals for measuring milk production, and they lend themselves readily to blood collection for measurement of 25 antibodies, circulating hormones or metabolites.

The following experiments compared responses of FEEDMIZA-immunised animals with non-immunised control animals.

Since stimulation of milk let-down (and 30 therefore measurable milk production) is dependent upon there being good vigorous sucking, and complete offtake of what milk is produced, it is desirable to use ewes with twin lambs. Studies involving the measurement of milk production were performed on a known high twinning 35 line of mature aged ewes, ensuring that adequate

- 59 -

numbers of twin-bearing ewes would be available for the experiments.

Experiment 1

5 This experiment was designed to measure the effect of immunising pregnant merino ewes three times during pregnancy, and comparing the weights of the ewes at first immunisation, at lambing and at "weaning" 6 weeks after lambing with comparable ewes and lambs that
10 have not been immunised.

Protocol

15 Twenty merino ewes that had been mated previously following synchronisation with intra-vaginal sponges (Repromap; Upjohn, Australia) were given an intra-muscular injection of pregnant mare serum gonadotropin (Folligon, Intervet, Melbourne, Australia). When the sponges were withdrawn, the animals were randomly allocated into two groups of 10 each (groups to
20 be immunised and to remain non-immunised) at 60 days of pregnancy. The animals were proven to be pregnant with twin lambs using an ultrasonic scanner.

25 The pregnant ewes were maintained on pasture during pregnancy as a single mob of sheep. Free choice was provided to lucerne hay during the last four weeks of pregnancy. Immediately after the sheep lambed they were moved indoors and offered 2.5 Kg per day of a 4:1 mixture of lucerne chaff and rolled barley until 6 weeks of age, at which point the experiment was concluded and
30 the ewes and lambs were turned out to pasture.

 The ewes which were to be immunised were injected with 3ml of FEEDMIZA subcutaneously in the flank at 90, 110 and 132 days of pregnancy.

- 60 -

The liveweights of the ewes were recorded at the time of first immunisation, at birth and at 6 weeks of age "weaning". Liveweights of the lambs were recorded at birth and at weaning.

5 Wool samples (100 square centimetres) were collected as mid side patches as described by Wynn et al (1988) at time of first immunisation, lambing and weaning of the ewes, and at weaning for the lambs. The follicle density and types were assessed by histological 10 examination of core samples collected at birth, 1 week of age and at weaning.

Milk production was measured one day of each week for the first 6 weeks of lactation by depriving the lambs access to their mothers for a period of 6 hours.

15 After the 6 hours of lamb deprivation the ewes were handmilked with the total weight of milk being recorded. A 10ml sample of this milk was taken for assay, and the remainder was fed to the lambs by hand using teats attached to the pen draining a pouch containing the 20 milk.

Results

The weights of the ewes at first immunisation were 57.3 ± 2.4 kg for the group to be immunised, and 25 57.5 ± 2.7 kg for the group to remain as non-immunised controls. At birth the immunised ewes weighed 53.2 ± 3.0 kg while the non-immunised group weighed 51.8 ± 2.7 kg. At weaning the immunised ewes weighed 55.2 ± 3.1 kg and the non-immunised group weighed 52.7 kg. There were no 30 statistically significant differences between the weights of the ewes at any stage of the experiment, nor was there any significant differences in the birthweights of the lambs. (4.4 ± 0.11 kg for the immunised groups compared with 4.4 ± 0.08 kg for those

- 61 -

in the non-immunised group). The weights of the lambs at weaning were 6.72 ± 0.8 kg in the non-immunised ewes, and 8.07 ± 1.0 kg in the immunised ewes, as shown in Figure 15. This difference in liveweights was 5 statistically significant ($P<0.05$).

The milk yields recorded for the ewes are presented in Figure 16 and show that the milk production of the immunised ewes was approximately 20% greater at each observation.

10 There was no statistically significant differences in the milk fat, milk lactose or milk protein levels measured in the samples of milk collected from the treatment groups at each milk collection. There were slight differences in the 15 analyses from week to week.

20 The yields of wool were approximately 10% heavier from the immunised ewes than from the non-immunised ewes during pregnancy, and during lactation. Yields of wool from the lambs consuming milk from the immunised ewes was 20% greater than that produced by the lambs drinking milk from the non-immunised ewes. In addition the wool which was harvested from the lambs from the immunised ewes was significantly finer than that which was observed from the non-immunised lambs. The 25 lambs on the immunised ewes had greater densities of secondary and primary follicles.

Discussion and conclusions

30 Immunisation of pregnant ewes with FEEDMIZA resulted in lambs which grew at a quicker rate of liveweight gain than was observed with the lambs produced by the non-immunised ewes. This was apparently associated with a greater quantity of milk produced by the ewes. The milk produced by the immunised ewes was of 35 normal analysis and therefore of equal nutritional value

- 62 -

compared with milk from non-immunised ewes. Immunised ewes produced more clean scoured wool during pregnancy and lactation, suggesting that there had been an effective improvement in nutritional status of the 5 immunised ewes during the period of gestation (improved wool production) and during lactation (improved wool and milk production). These favourable alterations to productivity are consistent with antibodies produced by the immunised ewes exerting their effects upon wool 10 follicle and lactogenic mammary cells.

The increased growth rates of lambs that were raised by the immunised ewes could be explained in that these lambs had more milk available to them, so presumably, they drank more milk. As this milk was of 15 normal analysis, these lambs took in more nutrients and were consequently receiving a higher plane of nutrition. This may not be the complete explanation since the colostrum and milk are also heavily laden with antibodies to FEEDMIZA. These antibodies may have 20 moderating effects on feed utilisation by the lambs.

Of enormous potential commercial significance for merino sheep is the observation that the lambs raised by the immunised ewes showed markedly increased densities of wool follicles in the skin. This change 25 would be one that persisted for life. Even more significantly the ratio of secondary to primary follicles was improved in favour of the secondary follicles, which are those which have been reported to be associated with production of the fine wool fibres. 30 This would suggest that these lambs have been permanently modified in favour of the production of more wool of a finer quality simply because they have been consuming large quantities of milk containing anti-FEEDMIZA antibodies for the first 6 weeks of life.

Example 20 Administration of Peptide SEQ ID NO:1 to
Cattle

This experiment was designed as a simple test to
5 see if vaccinating range-bred and reared-beef cattle
would result in heavier liveweights during pregnancy. A
further observation was to be made of the growth of
calves sucking cows which were immunised with FEEDMIZA
during gestation.

10

Protocol

A line of fifty Hereford x Angus heifers was
selected and placed onto actively growing pasture. The
heifers were oestrus synchronised by injecting with
15 Lutalyse (Upjohn, Rydalmer, Australia) and naturally
mated to Hereford bulls. The animals were randomly
divided into two groups at the time of synchronisation;
one group of 20 animals was to be the immunised group,
and a second group of 20 animals was the non-immunised
20 heifers.

Animals to be immunised were injected with 3ml
of emulsion subcutaneously in the neck at mating, 3
months of pregnancy and two weeks prior to parturition.

The animals were weighed at the time of mating,
25 at parturition and at 3 months after parturition. The
calves produced were weighed at birth and each 28 days
thereafter until 3 months old.

Results

30 The mean weights of the heifers at mating were
360 ± 8.5 kg for the non-immunised group, and 355 ± 12.8
kg for the group to be immunised.

At parturition the mean weights of the non-
immunised control animals was 385 ± 15.5 kg, and for the
35 immunised group was 440 kg for the immunised cows. (an

- 64 -

average difference of 22%) The mean weights of the cows 3 months after parturition were 375 ± 20.5 kg or the non-immunised animals, and 415 ± 24.5 kg or the immunised cows (an average difference of 10.6%)

5 Results are presented in Figure 17.

Mean birth weight of the non-immunised calves was 35 ± 3.5 kg compared with 40 ± 4.5 kg. (an average difference of 14%). Mean weights of the calves three months after birth were 116.2 ± 6.4 kg for the non-
10 immunised control group, and 145.0 ± 7.5 kg for the immunised group (an average difference of 20%). The average gain of the non-immunised calves for days 1-84 was 81.2 kg, and for the immunised group was 105 kg (an average difference of 23.8 kg, or 29.3%), as shown in
15 Figure 18.

20 Total net gain of liveweight (cow plus calf) from mating to 84 days after calving was 131.2 Kg for the non-immunised group, and 205 Kg for the immunised group.

20

Discussion and conclusions

25 Immunisation of range-bred and range-reared beef heifers with FEEDMIZA has resulted in the initiation of greater weight gains of these animals during pregnancy, and in the production of heavier calves at birth. The calves born to immunised or to non-immunised cows were both approximately 9% of the weight of the cow at birth. Calves sucking the vaccinated dams grew at a more rapid rate for the first 84 days after birth. This is a
30 similar pattern to that which has been observed following immunisation of pregnant sows or pregnant ewes, and provides further circumstantial evidence that FEEDMIZA has the potential to favourably alter the efficiency of beef breeding.

- 65 -

Example 21 Effects of different types of adjuvants

Lambs were immunised at 35kg liveweight with 0.5mg of SRIF conjugated to BSA (bovine serum albumin) 5 in a variety of delivery vehicles (adjuvants) at day 0, 21 and 42 (n=6 animals per group).

The growth responses measured over an 84 day period were:

non immunised controls	2.0 ± 1.37kg
FCA immunised	4.5 ± 1.60kg
MDP immunised	7.0 ± 1.3kg
FIA & MDP immunised	5.0 ± 1.3kg
DEAE immunised	3.5 ± 0.6kg
Quill A immunised	4.0 ± 1.5kg
Oil immunised	7.5 ± 1.2kg

10

It is concluded that the type of adjuvant used may have a bearing upon the efficacy of antibodies generated.

A significant response was observed when the oil 15 of the invention was used as the adjuvant. Immunised animals did not show any evidence of abscess formation, and indicates that it is a potential commercial preparation.

Other materials which could conceivably be used as 20 adjuvants, or additions to delivery vehicles to act as adjuvants are aluminium salts, lipopolysaccharides, sorbitan trioleate, Pluronics, Tetronics, squalene, liposomes, immunostimulatory complex, cholera toxin, heat labile toxin of *E. coli*, interleukins or the like.

25

- 66 -

Example 22 Effects of variations to antigen structure

The affinities of antibodies to SRIF, the cyclosised form of the preferred sequence (SEQ ID Nos 2 to 3) and the linear form (SEQ ID No. 4) were determined 5 for hyperimmune sheep and swine sera produced against each of the three presentations.

Antibodies Affinities of Antisera for Somatostatin

Affinities of the antibodies for somatostatin 10 were established using Scatchard plot analysis as described previously by Holst JJ, Jorgensen PN, Rasmussen TN & Schmidt P (1992), "Somatostatin restraint of gastrin secretion in pigs revealed by monoclonal antibody immunoneutralization". *American journal of Physiology* 263:G908-G912. Affinities for sheep and swine 15 antibodies which recognise and bind somatostatin are summarised below:

ANTIGEN	ANTIBODY	AFFINITY FOR SOMATOSTATIN
Anti-SRIF	sheep	$1.5 \times 10^{11} \pm 1.2 \times 10^1$ 1 mol ⁻¹
Anti-SRIF	swine	$2.0 \times 10^{10} \pm 1.4 \times 10^1$ 1 mol ⁻¹
Cyclosised	sheep	$1.9 \times 10^8 \pm 2.2 \times 10^1$ 1 mol ⁻¹
Cyclosised	swine	$3.0 \times 10^8 \pm 1.0 \times 10^1$ 1 mol ⁻¹
Linear	sheep	$1.3 \times 10^7 \pm 0.2 \times 10^2$ 1 mol ⁻¹
Linear	swine	$1.4 \times 10^7 \pm 1.6 \times 10^1$ 1 mol ⁻¹

20 It is evident from these data that the anti-SRIF antisera raised in sheep and swine gave rise to a much higher association constant than antisera raised in animals immunised with Cyclosised or the linear equivalent of the construct.

25 Antibody studies with SRIF and glucagon reveal that some cross-over effect occurs between both molecules. The structure of SRIF contains the sequence

- 67 -

S-T-F-T which is homologous with a portion of the glucagon molecule. Antibodies raised to the preferred peptide have no cross reactivity with glucagon.

5 Pregnant pigs which were immunized twice in the last trimester of pregnancy with SEQ ID Nos 3, 4,5 and SRIF 14 (native somatostatin) conjugate presented with the preferred oil all produced anti-SRIF antibodies in colostrum and milk of the sow and in the blood and gut scrapings of the piglets at 3 days and 21 days of age.

10 The absolute growth rates of the piglets from birth to weaning were:

Piglets from non-immunised 165 g per day n=40 control sows

Piglets from sows immunised 275 g per day n=42 with SEQ ID No:3

Piglets from sows immunised 240 g per day n=44 with SEQ ID No:4

Piglets from sows immunised 180 g per day n=42 with SRIF conjugate

15 Example 23 Effects of SEQ ID No 3 in piglets

The type of antibody produced in response to the cyclic peptide delivered in the preferred oil has a bearing upon the growth of the immunised animals compared to SRIF 14 conjugate delivered in the same 20 manner.

Sows immunized twice in the last trimester of pregnancy with SEQ ID No 3 produced piglets which were on average 27% heavier at weaning (at 21 days of age) than the offsprings of sows immunised with SRIF 14 25 conjugate vaccine. The levels of anti-SRIF antibodies measured are given below:

- 68 -

TREATMENT	DAY 3	DAY 21
Gut IgG (OD @ 405 nm ± SD)		
SRIF/BSA	0.684 ± 0.548	0.259 ± 0.18
SEQ ID NO:3	0.51 ± 0.21	0.123 ± 0.09
Gut IgA		
SRIF/BSA	0.189 ± 0.133	0.037 ± 0.05
SEQ ID NO:3	0.12 ± 0.157	0.10 ± 0.087
Plasma IgG		
SRIF/BSA	1.38 ± 0.44	1.779 ± 0.13
SEQ ID NO:3	0.9 ± 0.13	2.12 ± 0.23
Plasma IgA		
SRIF/BSA	1.067 ± 0.469	0.798 ± 0.49
SEQ ID NO:3	1.43 ± 0.217	0.567 ± 0.21
Sow's milk IgG		
SRIF/BSA	1.6 ± 0.22	
SEQ ID NO:3	1.4 ± 0.162	
Milk/colostrum IgA		
SRIF/BSA	0.029 ± 0.035	
SEQ ID NO:3	0.026 ± 0.028	

Significant quantities of antibodies to SRIF were detected in the plasma and gut scrapings of piglets sucking sows immunised with SRIF/BSA or SEQ ID NO:3 emulsified in the oil of the invention.

The results indicate that although the amount of antibody to SRIF, measured in colostrum, milk, gut scrapings or piglet serum up to weaning were similar,

- 69 -

the functionality of the antibodies was different, as evidenced by the difference in growth rates observed.

The peptides when administered (via
5 intramuscular, subcutaneous, intramammary, oral or
intraperitoneal delivery) to the vaccine recipient in
conjunction with or in the absence of any adjuvant or
immunostimulatory system, will elicit specific
antibodies which alter directly or indirectly the
10 endocrine systems associated with digestion and
subsequent metabolism of nutrients. However, the
preferred form of antigen delivery involves the
immunogens being mixed, suspended or preferably
emulsified in a non-macrophage stimulating system
15 injected either subcutaneously or intraperitoneally. An
important feature of the preferred delivery system is
that it facilitates the expression of the humoral immune
response to multiple antigens as if each was presented
alone. Furthermore, since the delivery system elicits
20 predominantly a humoral response, without involving
macrophage stimulation, the antibodies are extremely
potent (high titres and affinity) and involve the whole
complement of isotypes, especially those associated with
mucosal surfaces (IgA and IgM).
25

The mechanisms by which the invention improves
animal productivity are extremely complex and not
understood completely. However, it has been established
that the antibodies alter the metabolism of particularly
somatostatin, gastrin, insulin, and glucagon; and
30 augment the circulating concentrations of insulin-like
growth factor (IGF-I and II). The endocrine
ramifications associated with altering the metabolism of
these hormones are vast and include changes in the
circulating concentrations of, at least, gastrin,
35 cholecystokinin, motilin, secretin, the thyroid

- 70 -

hormones, glucagon, insulin, IGF I and II, somatostatin, prostaglandins, histamine, and vasoactive intestinal peptide. It has been demonstrated from the results obtained from our laboratory that immunisation against 5 the peptides induce changes in both gastrointestinal and metabolic functions. For example the rate of the secretion of gastric acid and the activity of many of the gastric proteases are retarded significantly in response to both chemical and physiological stimulation 10 following immunisation. In addition, the motility of digesta through various segments of the gastrointestinal tract are altered significantly and consequently the absorption and metabolism of key metabolites are enhanced. Furthermore, the antibodies allow many cells 15 particularly those associated with the endocrine system to be more responsive to Ca^{2+} ions, thus increasingly the secretion of hormones associated with the somatotropic axis and gastrointestinal tract. There is an improved capacity for cells to perform optimally even 20 though Ca^{2+} levels are suboptimal. The effect of this is that mRNA production within cells, especially muscle fibres, mammatrophs and somatotrophs are enhanced.

It is postulated that the combination of events observed in response to immunisation enhance digestion 25 and absorption of feedstuffs and subsequent metabolism of key metabolites leading to improve productive capacities of immunised animals.

Although the invention has been described in detail for the purposes of clarity, it will be understood that various modifications may be made by a 30 person skilled in the art without departing from the scope of the invention.

- 71 -

Table 2

Birth weights of piglets from sows immunised
during pregnancy with either
5 SSTR 1, SSTR 2, SSTR 3, SSTR 4 and SSTR 5
 antigens or placebo injections

	<u>TREATMENT</u>	<u>BIRTHWEIGHT</u>
	SSTR 1	1.5 ± 0.2 k
10	SSTR 2	1.65 ± 0.1 kg
	SSTR 3	1.7 ± 0.15 kg
	SSTR 4	1.5 ± 0.2 kg
	SSTR 5	1.7 ± 0.1 kg
15	Control	1.35 ± 0.2 kg

Table 3

Mean titres of anti-SSTR antibodies in the colostrum of immunised sows and in the plasma and gut scrapings of sucking piglets at 21 days of age

SAMPLE	CONTROL	SSTR 1	SSTR 2	SSTR 3	SSTR 4	SSTR 5
Plasma	0	3025	5412	2564	1248	6458
Gut	0	2000	1895	3654	1478	4785
Colostrum	0	5002	8425	7845	5784	8563

Table 4
 Mean numbers of primary and secondary follicles of lambs sucking ewes immunised
 against SSTR 2, 3 and/or placebo injections at birth and 6 weeks of age.

AGE	MEASUREMENT	CONTROL	IMMUNISED
B	Secondary follicle	57	67
i	Primary follicle	13	17
r	Total follicle	70	84
t	Secondary density	36 cm ⁻²	38 cm ⁻²
h	Primary density	8 cm ⁻²	10 cm ⁻²
	Total density	44 cm ⁻²	48 cm ⁻²
	Ratio S/P	5	4.5
6	Secondary follicle	95	118
w	Primary follicle	5	10
e	Total follicle	100	128
e	Secondary density	55	70
k	Primary density	3	4
s	Total density	58	74
	Ratio S/P	17	20

- 74 -

Table 5

5 Liveweight gains and average daily liveweight gains of
 female pigs immunised
 with FEEDMIZA by various routes of injection, and
 placebo injected pigs. (males)

	Treatment (kg)	n	Weight at 21 weeks
10	Placebo injected 90.8 ± 3.21	12	583 ± 24.1
15	Subcutaneous immunisation 110.5 ± 3.22	12	650 ± 24.2
	Intraperitoneal immunisation 104 ± 2.79	12	625 ± 21.0
20	Immunised intramuscularly 96 ± 2.61	12	600 ± 19.6

25 The heaviest group was those which had been
 immunised subcutaneously. They were significantly
 heavier than all other treatment groups ($p<0.05$). The
 pigs immunised by the intraperitoneal route were
 significantly heavier than those immunised
 intramuscularly and those given placebo injections
 30 ($p<0.05$). There was no significant difference between
 the intramuscularly immunised and the placebo groups.

- 75 -

Table 6

Liveweight gains and average daily gains for female pigs immunised with FEEDMIZA by varying routes of injection, and placebo injected pigs.

5

	Treatment (kg)	n	Weight at 21 weeks
	Average daily gain (grams)		
10	Placebo injected 92 ± 2.49	12	575 ± 18.79
15	Immunised subcutaneously 104 ± 2.79	12	650 ± 21.05
20	Immunised intraperitoneally 9.5 ± 2.1	12	597 ± 15.79
	Immunised intramuscularly 98.7 ± 2.49	12	617 ± 18.79

Heaviest liveweight was recorded in the group which had been immunised by the subcutaneous route.

25 This was significantly heavier ($p<0.05$) than the weight of the group immunised intramuscularly. The weights of both of these groups were significantly heavier ($p<0.05$) than the placebo injected group. There were no significant differences between the weights of the other 30 treatments.

- 76 -

REFERENCES

Cohick, W.S. and Clemons, D.R.
Annual ana Review of Physiology, 1993 55 131-153.

5
Crowe, M.A., Enright, W.J., and Roche, J.F.
Journal of Animal Science, 1995 73 2406-2417.

Dockray, G.J., and Taylor, I.L.
10 Gastroenterology, 1976 71 971-977.

Hoskinson, R.M., Rigby, R.D.G., Mattner, P.E., Huynh, V.L., D'Occhio, M., Neish, A., Trigg, T.E., Moss, B.A., Lindsey, M.J., Coleman, G.D., and Schwartzkoff, C.L.
15 Australian Journal of Biotechnology, 1990 4 166-176.

Kamoi, K., Hama, H., Ito, S., and Matsuoka, M.
Endocrinologia Japonica, 1977 24 239-243.

20 Kaushansky, A., Bauminger, S., Koch, Y., and Lindner, H.R.
Acta Endocrinologica, 1977 84 795-803.

Lindstedt, G.
25 European Journal of Endocrinology, 1994 130 429-432.

Melmed, S., Harada, A., Hershman, J.M., Krishnamurthy, G.T. and Blahd, W.H.
Journal of Clinical Endocrinology and Metabolism, 1980
30 51 358-363.

Meloen, R.H.
Livestock Production Science, 1995 42 135-145.

- 77 -

Moore, K.L., Armstrong, J.D., Harvey, R.W., Campbell, R.M., and Heimer, E.P
Domestic Animal Endocrinology, 1992 9 125-139.

5 Patel, Y.C.

In "Basic and Clinical Aspects of Neuroscience., Vol 4. Somatostatin" (C. Weil, E.E., Müller and M.O. Thorner, eds), 1992 1-16 Springer Verlag, Berlin.

10 Pekas, J.C. and Trout, W.E.

Journal of Animal Science, 1993 71 2499-2505.

Pell, J.M. and Aston, R.

Livestock Production Science, 1995 42 123-133.

15

Pell, J.M. and James, S

Journal of Endocrinology, 1995 146 535-541.

Reisine, T. and Bell, G.I.

20 Endocrine Reviews, 1995 16 427-442.

Scanlon, A.R., Sunderland, S.J., Martin, T.L., Goulding, D., O'Callaghan, D., Williams, D.H., Headon, D.R., Boland, M.P., Ireland, J.J. and Roche, J.F

25 Journal of Reproduction and Fertility, 1993 97 213-222.

Scaramuzzi, R.J., Davidson, W.G., and Van Look, P.F.A. Nature, 1997 269 807-808.

30 Thomson, D.L., Jr, Southern, L.L., St. George, R.L., Jones, L.S., and Garza, F., Jr
Journal of Animal Science, 1985 61 1498-1504.

- 78 -

Westbrook, S.L., Chandler, K.D. and McDowell, G.H.
Australian Journal of Agricultural Research, 1993 44
229-238.

5 Wynn, P.C., Shahneh, A.Z., Rigby, R.D.G., Behrendt, R.,
Giles, L.R., Gooden, J.M., and Jones, M.R
Livestock Production Science, 1995 42 247-254.

Wynn, P.C., Wallace, A.L.C., Kirby, A.C., Annison, E.F.
10 Effects of growth hormone administration on wool growth
of Marino sheep.
Australian Journal of Biological Sciences, 41 177-187.

- 79 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT: NORTHSTAR BIOLOGICALS PTY LTD

10 (ii) TITLE OF INVENTION: PEPTIDES, ANTIBODIES,
VACCINES & USES THEREOF

10

(iii) NUMBER OF SEQUENCES: 57

15

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: GRIFFITH HACK
(B) STREET: 509 ST KILDA ROAD
(C) CITY: MELBOURNE
(D) STATE: VICTORIA
(E) COUNTRY: AUSTRALIA
(F) ZIP: 3004

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
25 (D) SOFTWARE: PatentIn Release #1.0, Version
#1.30

30

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: AU PN9990
(B) FILING DATE: 22-MAY-1996
(C) CLASSIFICATION:

35

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: SANTER, VIVIEN
(C) REFERENCE/DOCKET NUMBER: JMW/SW:FP4656

40

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +61 3 9243 8300
(B) TELEFAX: +61 3 9243 8333

- 80 -

(2) INFORMATION FOR SEQ ID NO:1:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO
(v) FRAGMENT TYPE: N-terminal

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
Leu Cys Phe Trp Lys Thr Cys
1 5

(2) INFORMATION FOR SEQ ID NO:2:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: circular

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
40 Phe Cys Phe Trp Lys Thr Cys Phe Cys
1 5

- 81 -

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: circular

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

20 Cys Phe Trp Lys Thr Cys Ser Gly
1 5

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

40 Phe Trp Lys Thr Ser Gly Gly
1 5

- 82 -

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

20 Phe Trp Lys Thr Ser Thr Lys Thr Ser Thr Lys Trp Phe
1 5 10

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

40 Met Phe Pro Asn Gly Thr Ala Ser Ser Pro Ser
1 5 10

- 83 -

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

20 Gln Asn Gly Thr Leu Ser Glu Gly Gln Gly Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

40 Ala Glu Gln Asp Asp Ala Thr Val
1 5

- 84 -

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Phe Pro Asn Gly Thr Ala Ser Ser Pro Ser
20 1 5 10

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

40 Gln Asn Gly Thr Leu Ser Glu Gly Gln Gly Ser
1 5 10

- 85 -

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

10 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

20 Ala Glu Gln Asp Asp Ala Thr Val
1 5

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

25

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

40 Met Phe Pro Asn Gly Thr Ala Pro Ser Pro Thr
1 5 10

- 86 -

(2) INFORMATION FOR SEQ ID NO:13:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

10 (iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

20 Gln Asn Gly Thr Leu Ser Glu Gly Gln Gly Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:14:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

40 Ala Glu Gln Asp Asp Ala Thr Val
1 5

- 87 -

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

20 Met Asp Met Ala Asp Glu Pro Leu
1 5

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

40 Gln Thr Glu Pro Tyr Tyr Asp Leu Thr Ser Asn
1 5 10

- 88 -

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Gln Ile Ser Pro Thr Pro Ala Leu
20 1 5

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

40 Met Asp Leu Val Ser Glu Leu
1 5

- 89 -

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

20 Gln Thr Glu Pro Tyr Tyr Asp Leu Ala Ser Asn
1 5 10

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

40 Ala Ile Ser Pro Thr Pro Ala Leu
1 5

- 90 -

(2) INFORMATION FOR SEQ ID NO:21:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

20 Met Asp Met Ala Tyr Glu Leu Leu
1 5

(2) INFORMATION FOR SEQ ID NO:22:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

40 Gln Thr Glu Pro Tyr Tyr Asp Leu Thr Ser Asn
1 5 10

- 91 -

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

20 Ala Ile Ser Pro Thr Pro Ala Leu
1 5

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

40 Met Glu Met Ser Ser Glu Gln Leu
1 5

- 92 -

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

20 Gln Thr Glu Pro Tyr Tyr Asp Met Thr Ser Asn
1 5 10

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

40 Ala Ile Ser Pro Thr Pro Ala Leu
1 5

- 93 -

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

20 Met Glu Leu Thr Ser Glu Gln Phe
1 5

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

40 Gln Thr Glu Pro Tyr Tyr Asp Met Thr Ser Asn
1 5 10

- 94 -

(2) INFORMATION FOR SEQ ID NO:29:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

20 Ala Ile Ser Pro Thr Pro Ala Leu
1 5

(2) INFORMATION FOR SEQ ID NO:30:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

40 Met Asp Met Leu His Pro Ser
1 5

- 95 -

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

10 (iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

20 Ala Gly Pro Ser Pro Ala Gly Leu Ala Val Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

30 (iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

40 Pro Leu Pro Glu Glu Pro Ala Phe
1 5

- 96 -

(2) INFORMATION FOR SEQ ID NO:33:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Met Ala Thr Val Thr Tyr Pro Ser
1 5

20 (2) INFORMATION FOR SEQ ID NO:34:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

40 Ala Gly Thr Ser Leu Ala Gly Leu Ala Val Ser
1 5 10

- 97 -

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

20 Pro Leu Pro Glu Glu Pro Ala Phe
1 5

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

40 Met Ala Ala Val Thr Tyr Pro Ser
1 5

- 98 -

(2) INFORMATION FOR SEQ ID NO:37:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

20 Ala Gly Thr Ser Leu Ala Gly Leu Ala Val Ser
1 5 10

(2) INFORMATION FOR SEQ ID NO:38:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: C-terminal
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

40 Pro Leu Pro Glu Glu Pro Ala Phe
1 5

- 99 -

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

20 Met Ser Ala Pro Ser Thr Leu Pro Pro
1 5

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 11 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

40 Gly Pro Gly Asp Ala Arg Ala Ala Gly Met Val
1 5 10

- 100 -

(2) INFORMATION FOR SEQ ID NO:41:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

20 Thr Ser Leu Asp Ala Thr Val
1 5

(2) INFORMATION FOR SEQ ID NO:42:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

40 Met Asn Thr Pro Ala Thr Leu Pro Leu
1 5

- 101 -

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

20 Ser Asp Gly Thr Gly Thr Ala Gly Met Val
1 5 10

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

40 Thr Ser Leu Asp Ala Thr Val
1 5

- 102 -

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
5 (A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

20 Met Glu Pro Leu Phe Pro Ala
1 5

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:
25 (A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

35 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

40 Val Gly Pro Ala Pro Ser Ala Gly Ala Arg
1 5 10

- 103 -

(2) INFORMATION FOR SEQ ID NO:47:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

15 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

20 Ala Leu Pro Gln Glu Pro Ala Ser
1 5

(2) INFORMATION FOR SEQ ID NO:48:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

40 Met Glu Pro Leu Ser Leu Ala
1 5

- 104 -

(2) INFORMATION FOR SEQ ID NO:49:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

10 (iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

20 Val Gly Ser Ala Ser Pro Met Gly Ala Arg
1 5 10

(2) INFORMATION FOR SEQ ID NO:50:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: C-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

40 Thr Leu Pro Glu Glu Pro Thr Ser
1 5

- 105 -

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: circular

(ii) MOLECULE TYPE: peptide

10 (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: not relevant

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

X Tyr Asp Thr Lys Val Phe Cys Ser

1 5

Where X is Nme

(2) INFORMATION FOR SEQ ID NO:52:

25 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

40 Ala Tyr Met Gly Trp Ser Cys Thr Lys Trp Phe
1 5 10

- 106 -

(2) INFORMATION FOR SEQ ID NO:53:

5 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

20 Phe Trp Lys Thr Ser Lys His Trp Ser Tyr Gly Leu Arg
1 5 10
Asp Gly Cys
15

25 (2) INFORMATION FOR SEQ ID NO:54:

25 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Phe Arg Cys Pro Pro Cys Thr Glu Arg Leu Ala Ala
1 5 10

- 107 -

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

10 (iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

20 Glu Val Leu Phe Arg Cys Pro Pro Cys Thr Pro Glu
1 5 10

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

25 (A) LENGTH: 10 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

35 (iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

40 Gly Ala Gly Ala Val Gly Ala Pro Val Val
1 5 10

- 108 -

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 12 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: peptide

10 (iii) HYPOTHETICAL: NO

15 (iv) ANTI-SENSE: NO

15 (v) FRAGMENT TYPE: N-terminal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

20 Asp Glu Ala Ile His Cys Pro Pro Cys Ser Glu Glu
1 5 10

CLAIMS

1. A non-naturally occurring peptide with an amino acid sequence which is derived from, or is similar to a native animal hormone, carrier protein, binding protein or receptor for said hormone, wherein said peptide is capable of eliciting one or more antibodies which are able to modulate the activity of said hormone or receptor *in vivo*.
2. A peptide according to claim 1, wherein the native animal hormone is somatostatin.
3. A peptide according to claim 1 or claim 2, selected from the group consisting of one or more of peptide Nos. 1 to 53 as herein defined.
4. A peptide according to claim 3, wherein the peptide is a peptide selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:51.
5. A peptide according to any one of claims 2 to 4, wherein the antibodies modulate the activity of one or more hormone receptor selected from the group consisting of SSTR2, SSTR3 and SSTR5.
6. A peptide according to claim 1, wherein the binding protein is insulin-like growth factor binding protein (IGFBP).
7. A peptide according to claim 6, selected from the group consisting of peptide Nos. 54 to 57.
8. A peptide according to any one of claims 1 to 7, wherein the hormone, carrier protein binding protein or receptor therefor is of human origin.
9. A peptide according to any one of claims 1 to 8, coupled to a carrier to form a peptide/carrier complex.
10. A peptide according to claim 9, wherein the carrier is a multiple antigen peptide (MAP) system.
11. A peptide according to claim 10, wherein the MAP system comprises an oligomeric branching lysine core.

- 110 -

12. A peptide according to claim 11, wherein the MAP system comprises at least 18 branching lysine core.

13. An immunologically reactive molecule (IRM) which is specific for the peptide of any one of claims 1
5 to 12.

14. An immunologically reactive molecule according to claim 13, which molecule is selected from the group consisting of naturally occurring antibodies, recombinant antibodies, scantibodies, synthetic antibodies, fusion
10 antibodies, chimeric antibodies and functional fragments thereof.

15. A pharmaceutical composition comprising an immunogenically effective amount of the peptide or molecule according to any one of claims 1 to 14,
15 together with a pharmaceutically or veterinarily acceptable carrier.

16. A vaccine preparation comprising the peptide or molecule according to any one of claims 1 to 15.

17. A veterinarily or pharmaceutically acceptable
20 carrier, comprising shark oil which has immuno-adjuvant activity.

18. A carrier according to claim 17, wherein said oil is from deep sea sharks and stimulates antibody production in an epithelial or mucosal surface.

25 19. A carrier according to claim 17 or claim 18, wherein said oil comprises 30-50% diacylglycerol ethers

20. A carrier according to claim 19, comprising:
20-70% octadec - 9 - enylglyceryl ether
3-25% 1 - hexadecylglyceryl ether

30 1-15% hexadec - 7 - enylglyceryl ether
1.5-20% octadecyl glyceryl ether
1-15% eicosa - 9 - enylglyceryl ether
1-25% lecithin
1-25% DL alpha tocopherol acetate

- 111 -

0-3% 1, 2, 5 - dihydroxycholecalciferol
0-5% vitamin A
0-40% non-mineral oil.

21. A method of producing an immunogenic
5 composition, comprising the step of contacting a peptide
capable of eliciting an immune response with a carrier
according to any one of claims 17 to 20.

22. A method according to claim 21, wherein the
peptide is a peptide according to any one of claims 1 to
10 12.

23. A method of delivering to an animal a peptide
capable of eliciting an immune response, comprising the
step of administering said peptide together with an
effective amount of a carrier according to any one of
15 claims 17 to 20.

24. A method of modulating one or more hormonal
responses in an animal, comprising the step of
administering to said animal a hormone modulating
effective amount of a peptide or molecule according to
20 any one of claims 1 to 15.

25. A method according to claim 24, wherein the
hormonal response is a response to one or more hormones
selected from the group consisting of somatostatin,
gastrin, insulin, glucagon, prolactin, molitin,
25 cholecystokinin, secretin, prostaglandins, IGFBP, IGF-I,
IGF-II, growth hormone, thyroid hormone, luteinising
hormone (LHRM) and hormones of the adrenal gland.

26. A method of enhancing gastrointestinal function
in an animal, comprising the step of administering an
30 effective amount of a peptide based on SSTR and/or IGFBP
to said animal.

27. A method of increasing anabolism and/or body
weight in an animal, comprising the step of
administering an effective amount of a peptide based on
35 SSTR and/or IGFBP to said animal.

- 112 -

28. A method of increasing circulating insulin, IGF-I and/or IGF-III in an animal, comprising the step of administering an effective amount of a peptide based on SSTR and/or IGFBP to said animal.

5 29. A method of suppressing gastric enzymes in an animal, comprising the step of administering an effective amount of a peptide based on SSTR to said animal.

10 30. A method of increasing fibre production and optionally further altering the proportion of secondary to primary follicles in a fibre producing animal, comprising the step of administering an effective amount of a peptide based on SSTR and/or IGFBP to said animal.

15 31. A method of increasing milk production in a milk producing animal, comprising the step of administering an effective amount of a peptide based on SSTR and/or IGFBP to said animal.

20 32. A method of decreasing the activity of the c-fos gene and/or increasing the activity of the c-jun gene in an animal, comprising the step of administering an effective amount of a peptide based on SSTR to said animal.

25 33. A method of altering calcium metabolism in an animal, comprising the step of administering an effective amount of a peptide based on SSTR to said animal.

30 34. A method of stimulating an immune response to a hormone, carrier protein, binding protein or a hormone receptor in an animal wherein said immune response modulates hormone activity, said method comprising the step of administering an immune response inducing effective amount of a peptide according to any one of claims 1 to 13.

35. 35. A method of stimulating an antibody response to a hormone, carrier protein, binding protein or hormone

- 113 -

receptor, wherein said antibody response modulates hormone or receptor activity in an animal and wherein said antibody response results in antibodies being secreted on the mucosa of the animal and/or in the milk 5 of said animal, said method comprising the step of administering to said animal an antibody stimulating effective amount of the peptide of the invention.

36. A kit comprising a peptide according to any one of claims 1 to 13.

10 37. A kit comprising a molecule according to claims 13 or 14.

38. A kit according to claim 36 or claim 37, further comprising a shark oil which has immuno-adjuvant activity.




Figure 1

2/19




Figure 2

3/19




Figure 3

4/19




Figure 4

5/19




Figure 5

○ Control
● SSTR

6/19




Figure 6

7/19




Figure 7

8/19




Figure 8

SUBSTITUTE SHEET (RULE 26)




Figure 9

10/19




Figure 10




Figure 11

SUBSTITUTE SHEET (RULE 26)

12/19




Figure 12




Figure 13A




Figure 13B

15/19




Figure 14

16/19




Figure 15

17/19




Figure 16

18/19




Figure 17

19/19




Figure 18

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00312

A. CLASSIFICATION OF SUBJECT MATTER

Int Cl⁶: C07K 7/06, 14/655; A61K 38/02, 38/08, 38/10, 38/16, 38/31, 35/60, 39/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
WPAT database, Chemical Abstracts - Keywords below; DGENE - sequence + keywords

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
JAPIO, MEDLINE, DGENE (Derwent Genseq)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Invention 1 : Chemical Abstracts and DGENE - Sequence ID Nos: 1-57; Medline Keywords - Somatostatin, receptors (control terms)

Invention 2 : WPAT Database Keywords - somatostatin receptor/s or SSTR, Insulin growth factor binding protein or

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2206352 (SANDOZ LTD.) publ. 5 January 1989, epd. 29 June 1987 (see page 25)	29
X	BE 892315 (SANDOZ AG) publ. 1 September 1982, epd. 6 March 1981 (see page 19)	29
X	WO 92/13556 (GENENTECH INC) publ. 20 August 1992, epd 12 February 1991 (see Examples)	27

Further documents are listed in the continuation of Box C

See patent family annex

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
14 August 1997

Date of mailing of the international search report

22 AUG 1997

Name and mailing address of the ISA/AU
AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION
PO BOX 200
WODEN ACT 2606
AUSTRALIA Facsimile No.: (06) 285 3929

Authorized officer

JIM CHAN

Telephone No.: (06) 283 2340

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/AU 97/00312

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JP 07082162 (POLA CHEM IND INC) publ. 28 March 1995, epd. 10 September 1993 (see Abstract)	17-25
A	AU,B, 34269/93 (661110) (ARCH DEVELOPMENT CORPORATION) OPI. 28 July 1993, epd. 31 December 1991 (see entire document)	26-33
A	Diabète & Métabolisme, Vol. 21, No. 5, 1995, M. Binoux, "the IGF system in metabolism regulation", (see entire document)	27

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 97/00312

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Due to the broad scope of Claim 1, the International Search Authority finds that for economic reasons no meaningful search can be carried out for the said claim. Thus only Claims 2-38 have been searched

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The international application is directed to a group of inventions which are not linked by a single general inventive concept (Rule 13.1). The inventions are as follows:

- (1) Claims 1-16, 34-38 are directed to a non-naturally occurring peptide which can elicit an antibody that is able to modulate hormone or receptor activity or a method of stimulating such an antibody response.

continued on supplementary sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 97/00312

Continuation of Electronic databases

IGFBP; Medline and Chemical Abstracts Keywords - Insulin-like growth factor protein, insulin-like growth factor binding protein, insulin-like growth factor, Somatostatin receptors (control terms in Medline, indexing terms and biological and therapeutic roles in Chemical Abstracts).

Invention 3 : WPAT Database Keywords - IPC marks A61K-047/00, A61K-047/44, A61K-035/60 shark or fish oil; Chemical Abstracts and Medline Keywords - shark oil.

INTERNATIONAL SEARCH REPORT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International Application No.
PCT/AU 97/00312

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No II:

- (2) Claims 17-25 are directed to a veterinarian or pharmaceutically acceptable carrier comprising shark oil which has immuno-adjuvant activity.
- (3) Claims 26-33 are directed to the use of the peptides based on SSTR and/or IGFBP to modulate various hormone-induced activities e.g. enhancing gastrointestinal function, increasing anabolism, circulating insulin, altering calcium metabolism.

There does not appear to be a single inventive concept which links these claims and hence the international application is claiming more than one invention.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No.
PCT/AU 97/00312

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
GB	2206352	AU	18409/88	BE	1002663	CH	679045
		DK	3537/88	ES	2010283	FR	2617171
		GB	2206352	IL	86876	IT	1221065
		JP	1026599	LU	87262	NL	8801640
		NZ	225188	SE	8802413	ZA	8804655
		DE	3820770				
BE	892315						
WO	92/13556	AT	135587	CA	2101340	DE	69209277
		EP	571417	ES	2085001	JP	6505235
		US	5187151				
JP	07082162						
AU	34269/93 (661110)	EP	621874	JP	7503611	US	5436155
		WO	9313130				
END OF ANNEX							